



Sultanate of Oman  
Ministry of Health

# CANCER INCIDENCE IN OMAN 2020



دائرة الأمراض غير المعدية  
Department of Non-Communicable Diseases



Department of Non-Communicable Diseases  
Directorate General of Primary Health Care



Sultanate of Oman  
Ministry of Health

# Cancer Incidence in Oman 2020

*Prepared by*

**Dr. Najla Al-Lawati**  
**Nabil Al-Siyabi**  
**Salim Al-Wehaibi**

*Reviewers*

**Dr. Shadha Al-Raisi**  
**Dr. Bassim Al-Bahrani**  
**Dr. Badria Al- Rashdi**



**Department of Non-Communicable Diseases**  
**Directorate General of Primary Health Care**

December 2023

**The National Cancer Incidence reports are released annually by the National  
Cancer Registry in Oman.  
For queries please contact the National Cancer Registry.**

Department of Non-Communicable Diseases  
Directorate General of Primary Health Care  
Minstry of Health

Tel. +968 24946378  
Fax +968 24946379  
Email : mohdncd@gmail.com  
MOH website:www.moh.gov.om

## Report Summary 2020

---

We are delighted to present the 2020 cancer incidence data for Oman, obtained through a rigorous and standardized methodology. It is important to highlight that a typical global practice involves a delay of 2-4 years in releasing cancer incidence data, underscoring the steadfast commitment to stringent data validation and quality assurance processes and contributing to the reliability of the findings presented in the report.

All the estimated incidence rates of this report were based on 2020 estimated mid-year population and obtained from the Ministry of Health's annual health report. The total population was 4,602,777 of which 2,702,182 were Omanis and 1,900,595 were Non-Omanis.

The total number of all tumors registered in 2020 was 2,198. Of these 1,994 (90.7%) were among Omanis, 191 (8.7%) were Non-Omanis and only 13 (0.6%) cases were carcinoma in Situ. Of the 1,994 males' accounted for 930 cases (44.57%) and females' accounted for 1,064 (55.43%) cases. In children aged 14 years and below, 125 cases were reported.

The median age at diagnosis was 52 years. This was higher in male (median age of 58) than in females' (median age of 49). The crude incidence rates for all cancer among Omanis were 68.3 per 100,000 for males and 79.4 per 100,000 for females. The age-standardized rate, adjusted to the world standard population, was 109.6 per 100,000 for males and 111.4 per 100,000 for females.

Overall, breast cancer, predominantly female, was the most common cancer, with the median age at diagnosis is 47 years, followed by thyroid cancer and colorectal cancer.

The total updated registered cases for 2019 were 2,171 cases compared to 2,089 cases at the time of publication, with an increase of 82 cases.

## Acknowledgement

---

The release of the National Cancer Incidence reports would not be possible without the support of the countless teams in the hospitals who, through the regular provision of data and information, continue to contribute to the registration of cancer cases in Oman. The National Cancer Registry would like to express its immense gratitude to all healthcare providers and administrators in all hospitals in Oman. We also acknowledge and thank the reviewers of the National Cancer Incidence reports for their invaluable assistance and insights leading to the release of the Cancer Incidence reports every year.

The data of this edition of the cancer incidence report provides information on cancer diagnosis from the first year that followed the identification of the COVID-19 virus. The first cases of COVID-19 were reported in Oman in February 2020.

The National Cancer Registry would like to extend its gratitude to the cancer registry staff who continued working on collecting data despite the COVID-19 pandemic unprecedented challenges.

# **Ministerial Decision No. 222/ 2017 on Registration of Cancer Cases**

---

Based on the Royal Decree No. 36/ 2014 on determining the terms of reference of the Ministry of Health and the approval of its organizational structure, and The Ministerial Decision No.4/2001 on Notification of Cancer Cases, and for the public interest, the following have been decided:

**Article (1):** The following neoplasms are considered cancerous diseases or carcinoma in-situ numbered as per the 10th revision of the International Statistical Classification of Diseases & Related Health Problems (ICD-10):

- Malignant Neoplasms (C00-C79)
- In Situ Neoplasms (D00-D09)
- Neoplasms of Uncertain or Unknown Behaviour (D37- D48)

**Article No. (2):** If a person is clinically or surgically or laboratory diagnosed with cancer or suspected of having cancer or carcinoma in-situ, it should be reported to the Oman National Cancer Registry at the Non-communicable Diseases Department in the Directorate General of Primary Health Care on the attached form within (30) days from the date of diagnosis.

**Article No. (3):** Reporting of cancer cases mentioned in the aforesaid Article shall be the responsibility of the following:-

- a. The doctor who has examined the patient
- b. The technician of the laboratory where the sample was confirmed positive
- c. The Director or Head of the government health institution (Civil or Military) or private health institutions, in which the case was diagnosed.

**Article No. (4):** Recording of persons with cancer or suspected cases in the Oman National Cancer Registry shall be according to the disease classification and shall include their trinomial name, tribe name, surname, age, sex, nationality and addresses.

**Article No. (5):** The Oman National Cancer Registry records are confidential, no persons other than the Registry workers are allowed to view or disclose them except on the grounds of the public interest.

**Article (6):** The Ministerial Decision No. 4/2001 shall be cancelled and all that contravenes with this Decision or contradicts with its provision shall be cancelled.

**Article (7):** This Decision shall come into effect from the date of its issue, and shall be implemented by the competent each in his respective field of specialization.

Issued on: 21/03/1439H, Corresponding to: 10/12/2017

**Dr. Ahmed bin Mohammed bin Obaid Al Saidi**  
**Minister of Health**

## Contents

---

<b>Background Of The Sultanate Of Oman.....</b>	9
Geographical Features.....	9
Population Structure.....	9
<b>Oman National Cancer Registry .....</b>	13
Methods .....	13
1. Data Collection .....	13
2. Data-Coding, Entry and Validity Checks .....	13
3. Completeness of Data Reporting.....	14
4. Data Analysis.....	14
5. Definitions .....	15
<b>Trends of Cancer 2008-2020 .....</b>	20
<b>Overall Results .....</b>	24
Regional Distribution.....	25
Common Cancers in Omanis.....	34
<b>Basis of Diagnosis.....</b>	36
<b>Common Cancers by Governorate .....</b>	39
<b>Cancers by Sites .....</b>	41
Bone.....	42
Brain and Nervous System.....	44
Breast.....	46
Cervix.....	49
Colon.....	51
Esophagus .....	54
Head and Neck .....	56
Kidney and ureter.....	58
Larynx .....	60
Leukemia.....	62
Liver .....	64

Lymphoma .....	66
Ovary .....	70
Pancreas.....	72
Prostate.....	74
Skin .....	76
Stomach.....	77
Thyroid .....	80
Trachea, Bronchus and Lung .....	82
Urinary Bladder .....	85
Uterus .....	87
<b>Childhood Cancers .....</b>	<b>89</b>
<b>Cancer among Non-Omanis .....</b>	<b>94</b>

### Background Of The Sultanate Of Oman

#### **Geographical Features**

The Sultanate of Oman is located in the southeastern corner of the Arabian Peninsula. It has a coastal line extending almost 1,700 kilometers from the Strait of Hormuz in the north to the borders of the Republic of Yemen, overlooking three seas; the Arabian Gulf, the Sea of Oman and the Arabian Sea. The country borders Saudi Arabia and United Arab Emirates (UAE) in the west, the Republic of Yemen in the south, the Strait of Hormuz in the north and the Arabian Sea in the east. Besides, there are a number of scattered Omani islands in the Arabian Sea; the most important are Masirah and Al-Halaniyat.

The total area of the Sultanate of Oman is approximately 309,500 square kilometers, and it is the third largest country in the Arabian Peninsula. The Sultanate comprises varying topographic areas consisting of plains, wadis (dry river beds) and mountains. The most important area is the plain overlooking the Sea of Oman and the Arabian Sea, with an area of about 3% of the total area. The mountain ranges occupy almost 15% of the total land of Oman and are inhabited by about 5% of the population. The remaining area is mainly sand, wadis and desert (about 82% of the total area).

The climate differs from one area to another; it is hot and humid in the coastal areas in summer and hot and dry in the interior, except for the higher mountains and Dhofar Governorate, which enjoy a moderate climate throughout the year.

The Sultanate of Oman is administratively divided into 11 Governorates with 63 Wilayah. The 11 governorates are Muscat, Dhofar, Musandam, Ad Dakhliyah, Al Buraymi, A'Sharqiyah South and North, Al Batinah, South and North, A'Dhahirah, and Al Wusta.

#### **Population Structure**

The estimated mid-year population in 2020 was 4,602,777 of which 2,702,182 were Omanis and 1,900,595 were Non-Omanis (Table 1). The Omani population shows a sex ratio of 984 females per 1000 males. About 14.9 % of the population are under-5 years and 38.4 % are under-15 years. Only 3.8 % of the total Omani population are above the age of 65 years

Table 2 gives the population distribution of Omanis by region and gender, which was used to calculate incidence rates for different regions.

## Background

---


**Table 1: Age structure of the Omani Population 2020**

Age Group	Male	%	Female	%	Total	%
0 - 4	205,297	15.1	197,680	14.7	402,977	14.9
5 - 9	183,770	13.5	177,441	13.2	361,211	13.4
10 - 14	138,595	10.2	133,660	10.0	272,255	10.1
15- 19	112,344	8.2	108,979	8.1	221,323	8.2
20 – 24	111,908	8.2	107,942	8.1	219,850	8.1
25 – 29	124,543	9.1	121,459	9.1	246,002	9.1
30 – 34	120,911	8.9	118,079	8.8	238,990	8.8
35 – 39	103,135	7.6	101,259	7.6	204,394	7.6
40 – 44	76,741	5.6	76,864	5.7	153,605	5.7
45 – 49	51,062	3.7	48,592	3.6	99,654	3.7
50 – 54	34,651	2.5	35,306	2.6	69,957	2.6
55– 59	29,259	2.1	31,017	2.3	60,276	2.2
60 – 64	22,767	1.7	27,253	2.0	50,020	1.9
65 – 69	15,574	1.1	19,308	1.4	34,882	1.3
70 – 74	12,114	0.9	13,897	1.0	26,011	1.0
75+	19,230	1.4	21,545	1.6	40,775	1.5
<b>Total</b>	<b>1,361,901</b>	<b>100.00</b>	<b>1,340,281</b>	<b>100</b>	<b>2,702,182</b>	<b>100</b>

**Table 2: Population Distribution of Omanis by Governorates and Gender, 2020**

Region	Males	Females	Total
Muscat	269,466	266,779	536,245
North Al - Batinah	274,425	268,908	543,333
Ad - Dakhliyah	181,494	178,535	360,029
South Al - Batinah	174,827	172,694	347,521
Dhofar	107,754	105,143	212,897
South Ash - Sharqiah	112,197	110,027	222,224
North Ash - Sharqiyah	94,715	94,319	189,034
Adh -Dhahirah	80,532	79,774	160,306
Buraymi	36,596	35,360	71,956
Musanadam	17,378	16,508	33,886
Al - Wusta	12,517	12,234	24,751
<b>Total</b>	<b>1,361,901</b>	<b>1,340,281</b>	<b>2,702,182</b>

## Population Pyramid ,Oman, 2020



## Background

**Figure 2: Health Administrative Regions of The Sultanate of Oman**



This Map is not an Authority of International and Administrative Boundaries

### Oman National Cancer Registry

The Oman National Cancer Registry was established in 1985 as a hospital-based registry. Only cases treated in tertiary hospitals were registered. In 1996, with the establishment of the Department of Non-Communicable Diseases Surveillance and Control, the cancer registry was transferred and started functioning under the Directorate General of Health Affairs. New cancer notification forms were developed and distributed to all regional hospitals and sister institutions. In 2000, the registration form was simplified (see annex 2), printed and distributed to all institutions that could potentially report cancer cases. Two trained cancer registrars are responsible for data collection, coding and entry.

### Objective of Cancer Registry

1. To compile an accurate database on cancer incidence in The Sultanate of Oman.
2. To monitor cancer trends, which can guide policymakers in setting priorities for the control and management of cancer.
3. To provide researchers and clinicians with population-based information on the number and types of cancer cases and their geographical distribution within the Sultanate of Oman.

## Methods

### 1. Data Collection

#### a) Active Collection

The active collection involves the registry personnel visiting different sources and abstracting data on Cancer Registry Forms.

Being the largest tertiary centre for diagnosis and treatment of cancer, registrars visit the Royal Hospital twice a week and abstract data on the notification forms. Similarly, other tertiary hospitals like Khouda Hospital and Al-Nahda Hospital are visited monthly. A new National Oncology Centre was established in the Royal Hospital in November 2004, after which data is also collected from chemotherapy and radiotherapy lists. Patients diagnosed abroad are traced through the Oncology Outpatient Register at the Royal Hospital, and subsequently, data are extracted from their case notes. Details of patients treated abroad are obtained from the Department of Treatment Abroad, Ministry of Health.

#### b) Passive Reporting

Cancer notification was made mandatory in 2001 through a Ministerial Decision (4/2001). When a case of cancer is diagnosed, the attending physician of the relevant specialty or the medical records department at the regional hospital completes the notification forms and sends them to the registry. Other institutions like the Armed Forces Hospital and Sultan Qaboos University Hospital do similar passive reporting. In 2017, the above Ministerial Decision was updated (222/2017) to include all health (Civil or Military) institutions in Oman, including private hospitals. The cancer registrars frequently visit these institutions for data extraction of patients diagnosed in them.

### 2. Data-Coding, Entry and Validity Checks

Until 2001 all cancer cases were being coded using International Classification of Diseases for Oncology (ICDO-2) codes, 2nd Edition, with topography 'C' and morphology 'M' codes.

## Registry Methods

---

Data was entered in CanReg-3 programme, supplied by the International Agency for Research on Cancer(IARC),Lyon,France. Canreg-4 software programme and International Classification of Diseases for Oncology ICDO-3 began to be used in 2003, since it was introduced in October 2002. This programme has a duplicate entry checking facility, which avoids the same case being registered more than once. In 2016, the registry software was upgraded to CanReg5 (version 5.00.40). For this report, we used CanReg5 (version 5.00.42). Validity checks were performed for consistency between site/histology, gender/site, and age/site/histology combinations using the same version.

### **3. Completeness of Data Reporting**

Data are obtained from all hospitals with histopathology/cytology and hematology laboratories (Royal, al-Nahdha, Khoula, Sultan Qaboos and Sohar Hospitals) from copies of reports of patients diagnosed as cancer to the registry. Since mid-2001, the Sultan Qaboos University and Armed Forces Hospitals histopathology laboratories have also started sending reports.

Since the establishment of the National Oncology Center in November 2004, the chemotherapy and radiotherapy lists are also obtained once a week. Monthly hospital "admission–discharge" lists were sent from the tertiary hospitals. From 2003, similar lists were sent by all the regional hospitals. These lists help

in updating the registry and in updating the status of the patient (deceased or alive).


The list of patients with cancer on chemotherapy is obtained from tertiary hospitals. Details of missing data are sought from all of the above sources so that the registry can be updated.

### **4. Data Analysis**

Data is first checked for consistency and validity using the International Agency for Research on Cancer (IARC), 2008 software (Canreg-5.00.40 build1566). Frequency distribution and incidence tables are generated for Omanis only, using the Canreg-5 programme. Data for individual cancers are then exported in csv form to Stata software (version 14.2, Stata Corporation, TX, USA) to analyse incidence by region, gender and morphological types. The results for childhood cancers are presented for the whole Sultanate according to the diagnostic groups defined in the "International Classification of Childhood Cancers, third edition, 2005" Steliarova Foucher et al., 2005). Bar diagrams and graphs are made using Microsoft Excel version 2019 (Microsoft Corporation).

## Registry Methods

**Figure 3: Data flow into the national cancer registry**



The National Center for Statistics and information provides population denominators (by 5- year age group and gender by region), which are used for calculating incidence rates. Since the 2003 report, we have included four comprehensive tables showing the frequency as well as the incidence of cancers by site, from the year 2004 onwards.

## 5. Definitions

### Incidence

The number of new cancer cases in a defined population within a specific period.

### Date of Diagnosis

The date documented on the histopathology report. For clinical cases, the date of diagnosis is the date stated in patient's case notes .

### Population at Risk

Individuals who are susceptible to specific cancers.

### Crude incidence rate

The number of new cancer cases in the population occurring within a Gregorian calendar (1st January to 31st December) divided by the population at risk in the same period expressed per 100,000.

### Age-specific rate

Incidence rate in a specific age group.

### Age-standardized rate (ASR)

Age standardization is necessary when comparing several populations that differ with respect to age. Hence the World Standard Population of Segi, (Table 3) (Segi M.Cancer mortality for selected sites in 24 countries (1950-57). Sendai: Tohoku University, School of Medicine, 1960) was used to adjust the crude

## Registry Methods

incidence rates and to remove the confounding effect of age. Therefore, the age-adjusted rates (ASR) could be used for comparison purposes with other rates where the same world standard population was used, especially those issued by the World Health Organization's agency, the International Agency for Research on Cancer (IARC), in its periodic publication, Cancer Incidence in Five Continents.

### **Multiples primaries**

Two or more abnormal growths of tissue occurring simultaneously and may be found in the same or different sites.

### **Metastasis**

It is the distant spread of cancer from its original site to other body organs, including lymph nodes, skeletal and/or visceral organs.

### **Carcinoma in situ:**

A group of abnormal cells that remain in the place where they first formed. They have not spread.

**Table 3: Age Structure of the World Standard Population of Segi, used for Age-adjustment**

Age Group	Population
00-04	12,000
05-09	10,000
10-14	9,000
15-19	9,000
20-24	8,000
25-29	8,000
30-34	6,000
35-39	6,000
40-45	6,000
45-49	6,000
50-54	5,000
55-59	4,000
60-64	4,000
65-69	3,000
70-74	2,000
75+	2,000
<b>Total</b>	<b>100,000</b>

**Table 4: Stability of data overtime**

Publ.Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
2008	881												
2009	899	915											
2010	901	921	876										
2011	920	964	956	1187									
2012	935	987	1008	1293	1212								
2013	935	987	1009	1302	1242	1242							
2014	950	995	1039	1316	1271	1371	1394						
2015	958	1013	1050	1337	1295	1410	1507	1615					
2016	962	1017	1052	1339	1301	1418	1523	1691	1780				
2017	964	1020	1059	1345	1309	1425	1537	1725	1880	1892			
2018	965	1023	1061	1348	1309	1430	1541	1737	1891	1938	1911		
2019	965	1023	1061	1350	1309	1437	1550	1737	1909	1966	2012	2089	
<b>2020</b>	<b>967</b>	<b>1026</b>	<b>1065</b>	<b>1348</b>	<b>1313</b>	<b>1438</b>	<b>1556</b>	<b>1740</b>	<b>1921</b>	<b>1977</b>	<b>2041</b>	<b>2171</b>	<b>1994</b>
Max	967	1026	1065	1348	1313	1438	1556	1740	1921	1977	2041	2171	1994
Min	881	915	876	1187	1212	1242	1394	1615	1780	1892	1911	2089	1994
Average	938.6	990.9	1021.5	1316.5	1284.6	1396.4	1515.4	1707.5	1876.2	1943.3	1988	2130	1994
Max-Min	86	111	189	161	101	196	162	125	141	85	130	82	
% Max variatio	%9.16	%11.2	%18.5	%12.2	%7.9	%14	%10.70	%7.30	%7.50	%4.37	%6.50	%3.80	

The table shows the total number of registrations annually and the updated numbers for each year following publication


## Registry Methods

---


**Table 5: Updated cancer cases over years 2008-2020 (Omani)**

Years	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020
Frequency	967	1,026	1,065	1,348	1,313	1,438	1,556	1,740	1,921	1,977	2,041	2,171	1,994

**Figure 4: Trends of cancer cases 1996-2020 (Omani)**



**Figure 5: Trends of cancer ASR 1996-2020 (Omani)**



### Data quality indicators

Validity (accuracy): The proportion of cases in a dataset with a given characteristic which truly have the attribute.

It is estimated by :

1. Re-abstracting and recoding by checking on the accuracy of recording and correcting any obvious deficiencies.
2. Internal consistency – check program CanReg 5
3. Morphological verification MV% – the percentage of cases with a morphologically verified diagnosis.
4. Death certificate only (DCO%) – the percentage of cases for which the only information came from a death certificate.
5. Missing information – proportion or percentage of cases with missing data
  - Primary site uncertain (% PSU) – C26, C39, C48, C76, C80
  - Age , sex
  - Stage

**Table 6: Data quality indicators (Validity Table)**

(%) Indicators Percentage	2019	2020
Morphologically verified (%MV)	%98.61	%98.5
Death certificate only (%DCO)	%0.0	%0.0
Primary site uncertain (% PSU)	%0.9	%1.35
(%) Age unknown	%0.0	%0.0

## Registry Methods

**Table 7: Data Quality indicators exported from Canreg 5**

**OMAN National Cancer Registry (2020)**

**Data Quality Indicators**

### MALE

SITE	Cases	ASR	Var	SE	(%)MV	(%)CLIN	(%)DCO	ICD10
Mouth & pharynx	37	4.14	0.55	0.74	100	0	0	C00-14
Oesophagus	14	1.66	0.21	0.46	100	0	0	C15
Stomach	45	5.84	0.82	0.91	100	0	0	C16
Colon, rectum, anus	134	17.42	2.5	1.58	100	0	0	C18-21
Liver	42	5.84	0.88	0.94	61.9	38.1	0	C22
Pancreas	17	2.33	0.33	0.58	82.35	17.65	0	C25
Larynx	13	2.07	0.34	0.58	100	0	0	C32
Lung, trachea, bronchus	51	7.37	1.15	1.07	98.04	1.96	0	C33-34
Pleura & other thoracic	3	0.37	0.05	0.23	100	0	0	C37-38
Melanoma of skin	1	0.19	0.04	0.19	100	0	0	C43
Breast	11	1.58	0.25	0.5	100	0	0	C50
Prostate	71	10.07	1.51	1.23	100	0	0	C61
Testis	21	1.46	0.12	0.35	100	0	0	C62
Kidney & urinary NOS	11	1.54	0.25	0.5	100	0	0	C64-66,68
Bladder	46	5.91	0.82	0.91	100	0	0	C67
Brain & nervous system	40	3.69	0.42	0.65	100	0	0	C70-72
Thyroid	57	4.89	0.51	0.72	100	0	0	C73
III-defined	14	1.7	0.23	0.48	92.86	7.14	0	C76-80
Lymphoma	139	15.34	1.99	1.41	100	0	0	C81-85,90,88,96
Leukaemia	78	6.41	0.65	0.81	100	0	0	C91-95
All sites but C44	898	105.55	14.39	3.79	97.55	2.45	0	ALLbC44

### FEMALE

SITE	Cases	ASR	Var	SE	(%)MV	(%)CLIN	(%)DCO	ICD10
Mouth & pharynx	24	2.81	0.36	0.6	100	0	0	C00-14
Oesophagus	4	0.46	0.06	0.24	100	0	0	C15
Stomach	28	3.07	0.38	0.61	100	0	0	C16
Colon, rectum, anus	104	12.91	1.69	1.3	100	0	0	C18-21
Liver	20	2.67	0.37	0.61	75	25	0	C22
Pancreas	15	1.93	0.26	0.51	93.33	6.67	0	C25
Lung, trachea, bronchus	20	2.53	0.34	0.58	100	0	0	C33-34
Pleura & other thoracic	2	0.24	0.03	0.18	100	0	0	C37-38
Breast	266	27.32	3.16	1.78	100	0	0	C50
Cervix	30	3.5	0.45	0.67	100	0	0	C53
Corpus & Uterus NOS	42	5.2	0.69	0.83	100	0	0	C54-55
Ovary & adnexa	35	3.98	0.49	0.7	100	0	0	C56
Kidney & urinary NOS	16	1.57	0.18	0.42	100	0	0	C64-66,68
Bladder	9	1.13	0.15	0.38	100	0	0	C67
Brain & nervous system	48	4.88	0.57	0.75	100	0	0	C70-72
Thyroid	186	15.7	1.54	1.24	100	0	0	C73
III-defined	15	1.81	0.24	0.49	100	0	0	C76-80
Lymphoma	79	7.8	0.88	0.94	100	0	0	C81-85,90,88,96
Leukaemia	40	3.13	0.28	0.52	100	0	0	C91-95
All sites but C44	1036	108.14	12.74	3.57	99.32	0.68	0	ALLbC44

Cases of unknown age ( 0M/0F) were excluded from these analyses

# Trends of Cancer

**Table 8: Frequency of Cancers among Omani Males, 2008-2020**

SITE	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	ICD (10th)
Lip	1	0	1	2	1	2	0	0	2	2	1	3	0	C00
Tongue	4	3	4	4	4	12	6	14	5	10	10	1	10	C01-02
Mouth	6	8	3	8	7	5	11	6	7	16	8	13	15	C03-06
Salivary glands	2	1	2	0	2	2	2	5	5	3	2	1	1	C07-08
Tonsil	1	0	1	0	0	1	0	1	0	1	0	0	0	C09
Other oropharynx	1	1	1	2	0	1	1	3	1	0	2	2	4	C10
Nasopharynx	6	6	5	4	3	3	10	13	5	6	7	8	5	C11
Hypopharynx	1	3	0	0	0	0	1	3	3	0	0	1	2	C12-13
Pharynx unspecified	0	1	0	1	0	1	1	1	0	1	1	1	0	C14
Oesophagus	5	8	15	10	10	10	15	10	8	11	18	13	14	C15
Stomach	33	50	33	57	65	55	56	47	57	59	57	66	45	C16
Small intestine	0	2	2	5	3	3	4	11	7	2	3	7	7	C17
Colon	19	24	33	39	45	45	47	54	51	88	80	89	90	C18
Rectum	10	19	11	26	26	27	23	35	32	43	30	42	40	C19-20
Anus	2	1	1	3	4	4	2	1	4	7	4	1	4	C21
Liver	30	18	20	29	34	32	58	51	68	48	55	48	42	C22
Gallbladder etc	3	4	5	8	2	4	3	7	5	9	8	5	6	C23-24
Pancreas	8	10	14	17	16	23	13	18	22	28	19	19	17	C25
Nose, sinuses etc	1	1	1	3	0	0	0	1	1	4	3	1	3	C30-31
Larynx	4	4	12	7	7	8	7	8	17	8	8	8	13	C32
Trachea, bronchus and lung	29	30	25	44	34	42	50	44	58	62	52	63	51	C33-34
Other thoracic organs	1	3	0	5	0	2	3	1	3	1	2	3	3	C37-38
Bone	4	11	13	15	9	8	10	10	13	6	9	4	5	C40-41
Melanoma of skin	2	4	2	3	2	4	2	2	1	1	1	4	1	C43
Other skin	23	25	20	22	25	32	22	23	32	25	36	32	32	C44
Mesothelioma	1	0	0	4	1	1	2	1	2	3	2	4	1	C45
Kaposi sarcoma	2	3	2	7	1	4	0	2	2	2	1	1	1	C46
Connective and soft tissue	8	4	10	7	9	8	12	19	8	11	12	15	16	C47,C49
Breast	1	5	8	6	8	5	10	6	8	6	9	12	11	C50
Penis	1	0	1	0	0	0	1	1	0	0	2	0	2	C60
Prostate	41	49	50	71	84	84	84	90	100	106	94	118	71	C61
Testis	7	6	7	10	6	9	11	13	9	13	18	16	21	C62
Other male genital organs	1	1	0	0	0	0	0	1	1	0	0	0	0	C63
Kidney	7	18	22	14	15	16	26	21	16	19	32	36	11	C64
Renal pelvis	0	0	0	0	0	0	0	1	0	0	1	0	0	C65
Ureter	0	0	0	0	1	0	0	1	0	1	0	2	0	C66
Bladder	25	26	36	35	35	48	53	43	52	61	45	61	46	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	1	0	0	C68
Eye	2	1	0	3	1	1	0	2	2	3	1	2	2	C69
Brain, nervous system	14	23	18	20	29	18	30	26	31	30	30	30	40	C70-72
Thyroid	12	13	4	12	17	19	32	31	47	30	48	54	57	C73
Adrenal gland	0	3	6	4	6	4	3	6	4	5	5	4	6	C74
Other endocrine	0	1	0	0	0	1	2	0	2	0	0	3	0	C75
Hodgkin disease	18	17	17	24	27	20	26	30	37	40	27	28	35	C81
Non-Hodgkin lymphoma	45	42	41	57	55	55	64	67	63	69	56	50	76	C82-85,C96
Immunoproliferative diseases	1	0	0	1	0	0	0	1	1	0	4	0	5	C88
Multiple myeloma	9	9	9	7	13	15	10	11	8	12	15	21	23	C90
Lymphoid leukaemia	26	32	25	36	15	20	33	28	37	25	32	25	29	C91
Myeloid leukaemia	17	14	15	27	18	17	20	29	25	27	30	26	35	C92-94
Leukaemia unspecified	2	1	3	2	2	4	1	0	4	4	0	6	14	C95
Myeloproliferative disorders	1	1	2	1	0	0	0	1	1	2	0	1	1	MPD
Myelodysplastic syndromes	0	0	2	0	0	0	1	1	0	0	0	0	0	MDS
Other and unspecified	17	21	13	26	22	17	8	15	24	21	22	17	17	O&U
All sites	454	527	515	688	664	692	776	816	891	931	903	967	930	ALL
All sites but C44	431	502	495	666	639	660	754	793	859	906	867	935	898	ALLbC44

## Trends of Cancer

**Table 9: Frequency of Cancers among Omani Females, 2008-2020**

SITE	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	ICD (10th)
Lip	2	0	0	0	2	0	0	2	1	2	0	1	0	C00
Tongue	2	2	4	4	3	1	6	6	1	4	4	3	9	C01-02
Mouth	3	5	4	3	4	5	8	3	8	7	2	5	6	C03-06
Salivary glands	2	2	2	3	1	1	2	4	1	4	1	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	1	2	0	0	0	C09
Other oropharynx	0	0	0	0	0	1	0	0	0	1	0	1	2	C10
Nasopharynx	4	3	5	3	3	1	2	6	3	4	1	2	5	C11
Hypopharynx	1	0	0	0	0	0	2	0	0	0	1	0	1	C12-13
Pharynx unspecified	1	0	0	1	0	1	0	0	0	0	0	1	1	C14
Oesophagus	6	8	5	4	9	3	3	5	3	3	8	7	4	C15
Stomach	15	24	23	25	29	31	35	23	26	35	31	53	28	C16
Small intestine	2	1	1	2	3	4	0	2	3	5	2	6	5	C17
Colon	22	24	16	23	43	28	49	49	49	63	69	66	78	C18
Rectum	10	12	19	16	17	24	25	24	31	27	36	25	26	C19-20
Anus	1	1	2	3	0	0	2	2	1	4	2	3	0	C21
Liver	5	16	15	11	14	17	33	30	35	22	27	24	20	C22
Gallbladder etc	6	6	2	6	8	4	7	5	11	13	7	7	6	C23-24
Pancreas	7	4	5	8	9	15	11	11	12	15	22	21	15	C25
Nose, sinuses etc	0	4	1	1	0	0	1	2	2	0	3	0	1	C30-31
Larynx	0	3	1	0	1	2	1	3	0	2	0	4	0	C32
Trachea, bronchus and lung	11	15	8	14	20	17	16	20	18	34	26	21	20	C33-34
Other thoracic organs	2	0	1	1	3	0	1	3	2	2	1	1	2	C37-38
Bone	2	1	3	8	9	12	6	1	12	4	11	10	17	C40-41
Melanoma of skin	2	2	2	4	1	1	0	3	1	2	4	1	0	C43
Other skin	16	19	24	20	20	24	20	32	28	30	29	31	28	C44
Mesothelioma	0	0	0	0	0	0	1	1	1	1	1	1	3	C45
Kaposi sarcoma	2	1	1	0	0	1	0	0	1	1	0	0	0	C46
Connective and soft tissue	5	3	4	3	10	8	4	12	14	11	8	14	8	C47,C49
Breast	125	125	139	162	158	184	177	223	279	278	299	347	266	C50
Vulva	0	0	1	0	2	2	0	0	1	2	2	1	1	C51
Vagina	2	0	0	2	4	1	3	1	2	4	0	1	1	C52
Cervix uteri	30	13	36	31	26	26	32	34	34	32	29	34	30	C53
Corpus uteri	13	13	16	24	15	16	19	25	32	27	40	42	30	C54
Uterus unspecified	6	2	3	6	5	5	7	7	7	7	12	10	12	C55
Ovary	20	16	22	23	22	32	38	39	32	24	42	47	35	C56
Other female genital organs	0	0	0	0	0	2	0	1	1	2	1	0	1	C57
Placenta	0	1	0	3	1	0	1	1	3	0	5	0	2	C58
Kidney	17	8	9	21	10	16	16	17	13	20	22	25	16	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	1	0	1	0	0	0	0	1	0	0	0	C66
Bladder	10	10	9	8	11	10	15	12	16	16	14	15	9	C67
Other urinary organs	0	0	0	0	1	0	0	0	1	1	0	0	0	C68
Eye	1	1	2	3	2	2	1	0	2	2	3	2	2	C69
Brain, nervous system	14	12	20	14	8	13	18	20	30	25	30	22	48	C70-72
Thyroid	41	52	40	74	75	111	99	145	166	161	163	198	186	C73
Adrenal gland	4	1	1	4	3	3	2	4	6	6	6	11	2	C74
Other endocrine	0	0	0	0	1	0	1	0	0	0	0	0	1	C75
Hodgkin disease	15	11	14	23	10	21	15	17	17	14	21	24	25	C81
Non-Hodgkin lymphoma	30	31	41	41	29	35	34	59	46	47	52	46	42	C82-85,C96
Immunoproliferative diseases	0	0	0	0	1	1	1	2	3	1	3	1	0	C88
Multiple myeloma	3	6	6	5	11	9	6	13	11	6	12	19	12	C90
Lymphoid leukaemia	21	10	15	13	19	19	22	21	18	29	21	15	19	C91
Myeloid leukaemia	14	13	18	16	15	17	19	20	20	17	28	21	14	C92-94
Leukaemia unspecified	3	3	0	3	0	2	5	0	2	3	2	1	7	C95
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	3	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	11	15	9	20	10	18	14	14	23	23	35	14	18	O&U
All sites	513	499	550	660	649	746	780	924	1030	1046	1138	1204	1064	ALL
All sites but C44	497	480	526	640	629	722	760	892	1002	1016	1109	1173	1036	ALLbC44

## Trends of Cancer

**Table 10: Age-adjusted Incidence Rates in Omani Males, 2008-2020**

SITE	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	ICD (10th)
Lip	0.1	0	0.3	0.4	0.1	0.2	0	0	0.2	0.2	0.1	0.3	0	C00
Tongue	1.2	0.7	0.8	0.9	0.7	2.1	0.8	2.2	0.5	1.3	1.1	0.2	1.1	C01-02
Mouth	1.3	1.7	0.7	1.7	1.2	0.6	1.5	0.7	0.9	2.4	1.2	1.7	1.7	C03-06
Salivary glands	0.3	0.2	0.5	0	0.3	0.4	0.2	0.5	0.5	0.3	0.3	0.1	0.1	C07-08
Tonsil	0.2	0	0.2	0	0	0.1	0	0.2	0	0.2	0	0	0	C09
Other oropharynx	0.3	0.2	0.2	0.4	0	0.2	0.2	0.5	0.1	0	0.3	0.4	0.5	C10
Nasopharynx	1.5	1.1	0.8	0.8	0.4	0.3	1.5	1.9	0.6	0.8	1	0.8	0.5	C11
Hypopharynx	0.3	0.7	0	0	0	0	0.1	0.5	0.4	0	0	0.2	0.2	C12-13
Pharynx unspecified	0	0.2	0	0.2	0	0.1	0.1	0.2	0	0.1	0.2	0.1	0	C14
Oesophagus	1.3	2.1	4	2.3	1.8	1.5	2.2	1.5	1.2	1.7	2.7	2	1.7	C15
Stomach	8.8	13.1	7.8	13.7	11.5	8.1	9.3	6.2	7.8	8.4	8	8.2	5.8	C16
Small intestine	0	0.5	0.4	1.1	0.4	0.6	0.7	1.7	1.1	0.2	0.5	0.8	1.1	C17
Colon	4.4	5.2	6.6	7.5	7.3	6.7	7	7.5	7.2	12.1	10.6	11.8	11.8	C18
Rectum	2.4	4.8	2.4	5.5	4.1	4.6	3	5.4	4.2	5.7	4.2	5.6	5.1	C19-20
Anus	0.5	0.2	0.3	0.7	0.6	0.6	0.3	0.2	0.7	1.1	0.4	0.2	0.4	C21
Liver	8.1	4.3	4.3	6.4	5.5	5	9.1	7.7	10.2	7.2	8	6.8	5.8	C22
Gallbladder etc	0.9	1	1.3	2.2	0.3	0.6	0.5	1.1	0.9	1.2	1.2	0.8	0.9	C23-24
Pancreas	2.3	2.4	3.4	3.9	2.7	3.8	2.3	2.7	3.4	3.7	2.7	2.5	2.3	C25
Nose, sinuses etc	0.1	0.2	0.2	0.7	0	0	0	0.2	0.2	0.3	0.5	0.2	0.4	C30-31
Larynx	1.1	0.8	2.7	1.6	1.1	1.2	1.2	1.2	2.6	1.3	1.2	0.9	2.1	C32
Trachea, bronchus and lung	7.8	7.8	6.3	11.2	5.4	7.3	8.5	7.2	9	9.5	8.1	9	7.4	C33-34
Other thoracic organs	0.1	0.7	0	1.2	0	0.2	0.4	0.1	0.2	0.1	0.1	0.2	0.4	C37-38
Bone	0.3	1	1.4	1.6	0.7	0.7	0.8	0.7	1.1	0.4	0.8	0.3	0.4	C40-41
Melanoma of skin	0.5	0.8	0.6	0.7	0.4	0.7	0.2	0.3	0.1	0.1	0.1	0.5	0.2	C43
Other skin	5.7	6.2	5.2	4.8	3.7	4.5	3.2	3.2	4	2.9	4.6	4.2	4	C44
Mesothelioma	0.3	0	0	0.9	0.1	0.2	0.3	0.2	0.3	0.4	0.3	0.7	0.2	C45
Kaposi sarcoma	0.5	0.7	0.3	1.4	0.1	0.6	0	0.1	0.1	0.3	0.2	0.1	0	C46
Connective and soft tissue	1.2	0.5	1.4	1.2	0.7	0.9	1.1	2	1	1	1.4	1.2	1.5	C47,C49
Breast	0.1	1.4	2	1.3	1.4	0.8	1.8	1	1	0.7	1.3	1.7	1.6	C50
Penis	0.3	0	0.3	0	0	0	0.1	0.1	0	0	0.2	0	0.2	C60
Prostate	12.3	13.3	13.3	18.5	13.9	14.2	13.3	14.1	14.6	15.7	13.6	17.4	10.1	C61
Testis	0.7	0.5	0.5	0.7	0.4	0.8	0.9	0.9	0.7	1	1.6	1.3	1.5	C62
Other male genital organs	0.1	0.1	0	0	0	0	0	0.1	0.2	0	0	0	0	C63
Kidney	2	3.9	4.4	2.6	2.2	2.2	3.6	2.8	1.5	2.3	4.2	4.1	1.5	C64
Renal pelvis	0	0	0	0	0	0	0	0.2	0	0	0.2	0	0	C65
Ureter	0	0	0	0	0.2	0	0	0.2	0	0.1	0	0.2	0	C66
Bladder	6.9	6.7	9.1	8.7	6	7.8	8.3	6.7	7.9	9.1	6.5	8.1	5.9	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0.2	0	0	C68
Eye	0.3	0.1	0	0.2	0.1	0.2	0	0.2	0.1	0.2	0.1	0.1	0.1	C69
Brain, nervous system	1.8	3.4	2.6	2.8	3.5	2.3	3.5	2.6	3.1	2.7	2.7	3.1	3.7	C70-72
Thyroid	2	1.7	0.8	2.4	2	2.4	3.3	2.9	4.3	2.9	4.9	4.5	4.9	C73
Adrenal gland	0	0.3	0.7	0.3	0.7	0.3	0.4	0.4	0.3	0.3	0.3	0.2	0.4	C74
Other endocrine	0	0.1	0	0	0	0.1	0.2	0	0.2	0	0	0.2	0	C75
Hodgkin disease	3	1.7	1.8	3.7	3	2.1	2.7	2.4	3.5	3.7	2.5	2.4	2.9	C81
Non-Hodgkin lymphoma	9.8	7.6	7.6	11	7.9	7.3	8.7	8.8	7.4	7.3	6.3	5.4	8.8	C82-85,C96
Immunoproliferative diseases	0.3	0	0	0.3	0	0	0	0.1	0.1	0	0.5	0	0.6	C88
Multiple myeloma	2.5	2.4	1.8	1.8	2.2	2.5	1.5	1.4	1.3	1.9	2.3	3.1	3	C90
Lymphoid leukaemia	2.5	3.8	2.8	5.1	1.7	1.9	3.2	2.4	3	2.2	2.8	1.8	2.1	C91
Myeloid leukaemia	3.3	1.9	2.3	4.3	2.4	2	2.5	2.7	2.4	2.8	3.3	2.8	3.4	C92-94
Leukaemia unspecified	0.2	0.3	0.2	0.3	0.2	0.6	0.1	0	0.4	0.3	0	0.4	0.9	C95
Myeloproliferative disorders	0.3	0.3	0.5	0.1	0	0	0	0.1	0.1	0.1	0	0.1	0.1	MPD
Myelodysplastic syndromes	0	0	0.6	0	0	0	0.1	0.1	0	0	0	0	0	MDS
Other and unspecified	4.1	5	3.1	5.9	3.9	2.7	1.1	2.2	3.2	2.8	2.6	2	2.2	O&U
All sites	104	111.7	106.3	143.1	100.7	101.9	109.7	108.2	113.6	119	115.7	118.4	109.6	ALL
All sites but C44	98.3	105.6	101.1	138.3	97	97.5	106.5	105	109.6	116.1	111.1	114.2	105.6	ALLbC44

## Trends of Cancer

**Table 11: Age-adjusted Incidence Rates in Omani Females, 2008-2020**

SITE	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	ICD (10th)
Lip	0.5	0	0	0	0.3	0	0	0.2	0.1	0.3	0	0.1	0	C00
Tongue	0.3	0.3	0.8	1	0.5	0.2	1	0.7	0.2	0.5	0.4	0.3	1.2	C01-02
Mouth	0.8	1.5	0.9	0.7	0.7	0.9	1.2	0.4	1	1	0.2	0.5	0.6	C03-06
Salivary glands	0.2	0.3	0.2	0.6	0.1	0.2	0.2	0.4	0.1	0.3	0.1	0	0	C07-08
Tonsil	0	0	0	0	0	0	0	0	0.1	0.2	0	0	0	C09
Other oropharynx	0	0	0	0	0	0.1	0	0	0	0.1	0	0.1	0.3	C10
Nasopharynx	1	0.6	0.4	0.6	0.4	0.1	0.3	0.7	0.4	0.4	0.2	0.2	0.5	C11
Hypopharynx	0.3	0	0	0	0	0	0.3	0	0	0	0.2	0	0.1	C12-13
Pharynx unspecified	0.3	0	0	0.2	0	0.1	0	0	0	0	0	0.1	0.2	C14
Oesophagus	1.7	2.4	1.1	1.2	1.6	0.5	0.5	0.6	0.5	0.3	1	0.9	0.5	C15
Stomach	4.1	6	5.5	5.1	4.8	4.5	5.6	3.1	3.4	4.5	3.7	6.3	3.1	C16
Small intestine	0.6	0.3	0.2	0.5	0.5	0.5	0	0.2	0.5	0.6	0.2	0.6	0.6	C17
Colon	4.3	4.9	2.8	4.6	7.4	4.1	7.1	7	6.8	8.2	8.2	8.1	9.6	C18
Rectum	2.1	2.6	4.1	3.2	2.6	3.7	3.8	3.2	4.5	3.4	4.5	3.1	3.3	C19-20
Anus	0.3	0.3	0.6	0.6	0	0	0.3	0.2	0.1	0.5	0.2	0.3	0	C21
Liver	1.7	3.8	3.6	2.3	2.2	2.7	5	4.5	4.8	3.1	3.6	2.7	2.7	C22
Gallbladder etc	1.5	1.4	0.6	1.1	1.3	0.7	1.1	0.7	1.4	1.6	1	1	0.7	C23-24
Pancreas	1.6	1	1.3	1.9	1.5	2.6	1.8	1.7	1.5	2	2.9	2.8	1.9	C25
Nose, sinuses etc	0	1.1	0.3	0.2	0	0	0.1	0.3	0.3	0	0.2	0	0.1	C30-31
Larynx	0	0.8	0.1	0	0.2	0.4	0.2	0.4	0	0.2	0	0.5	0	C32
Trachea, bronchus and lung	3	3.7	2	3.6	3.6	2.7	2.5	2.9	2.6	4.6	3.6	2.7	2.5	C33-34
Other thoracic organs	0.5	0	0.1	0.1	0.4	0	0.1	0.2	0.2	0.1	0.1	0.1	0.2	C37-38
Bone	0.1	0.1	0.3	0.9	0.8	1.3	0.5	0.1	1.3	0.3	0.9	0.8	1.5	C40-41
Melanoma of skin	0.5	0.4	0.4	0.6	0.2	0.2	0	0.4	0.2	0.2	0.4	0.1	0	C43
Other skin	5	4.8	5.2	3.9	3.4	3.9	3	4.4	3.6	3.6	3.6	3.8	3.2	C44
Mesothelioma	0	0	0	0	0	0	0.1	0.2	0.2	0.1	0.1	0.1	0.4	C45
Kaposi sarcoma	0.7	0.4	0.3	0	0	0.2	0	0	0.2	0.1	0	0	0	C46
Connective and soft tissue	0.7	0.3	0.3	0.2	1.2	1	0.5	1.2	1.2	0.8	0.7	1.4	0.8	C47,C49
Breast	26	24	25	27.9	24.6	25.8	22.8	28.6	32.9	31.6	33.7	36.2	27.3	C50
Vulva	0	0	0.2	0	0.3	0.3	0	0	0.1	0.2	0.2	0.1	0.1	C51
Vagina	0.8	0	0	0.1	0.7	0.1	0.5	0.2	0.3	0.6	0	0.2	0.1	C52
Cervix uteri	7.1	2.8	7.4	6.1	4.2	4	4.8	4.7	4.9	4.4	3.5	4	3.5	C53
Corpus uteri	3.2	3.5	3.5	6	2.4	2.7	2.9	3.8	4.2	3.4	4.8	5.3	3.6	C54
Uterus unspecified	1.4	0.4	0.7	1.2	0.7	0.7	1.2	1.1	1	0.8	1.4	1.3	1.6	C55
Ovary	3.4	2.6	3.7	3.7	3	4	4.6	4.9	3.6	2.6	4.6	5.4	4	C56
Other female genital organs	0	0	0	0	0	0.3	0	0.2	0.1	0.2	0.1	0	0.1	C57
Placenta	0	0.2	0	0.4	0.1	0	0.1	0.2	0.4	0	0.3	0	0.1	C58
Kidney	4	1.7	1.5	3.1	1.2	2.4	2.2	2.3	1.5	2	2.2	2.6	1.6	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0.2	0	0.2	0	0	0	0	0.2	0	0	0	C66
Bladder	2.8	2	1.8	2	1.5	1.5	2	1.6	2.2	2	1.6	1.7	1.1	C67
Other urinary organs	0	0	0	0	0.2	0	0	0	0.2	0.1	0	0	0	C68
Eye	0.2	0.3	0.4	0.4	0.2	0.2	0.1	0	0.1	0.1	0.3	0.2	0.2	C69
Brain, nervous system	1.9	1.4	3	2.2	1	1.2	2	1.8	2.7	2.6	2.8	2.2	4.9	C70-72
Thyroid	5.2	6.7	5.2	9.2	7.8	12.4	10.7	15.2	16.3	15.5	13.7	16.6	15.7	C73
Adrenal gland	0.4	0.1	0.1	0.4	0.3	0.2	0.1	0.4	0.5	0.4	0.4	0.8	0.2	C74
Other endocrine	0	0	0	0	0.1	0	0.1	0	0	0	0	0	0.1	C75
Hodgkin disease	2.6	1.8	1.4	3.3	1	2.2	1.5	1.6	1.9	1.2	1.9	2	1.9	C81
Non-Hodgkin lymphoma	5.8	5.9	7.9	7.3	4.3	5.4	4.2	7.4	5.2	5.3	5.8	4.7	4.4	C82-85,C96
Immunoproliferative diseases	0	0	0	0	0.2	0.2	0.2	0.2	0.5	0.2	0.5	0.2	0	C88
Multiple myeloma	0.9	1.6	1.5	1	1.8	1.4	1	1.8	1.6	1	1.6	2.4	1.5	C90
Lymphoid leukaemia	2.4	1.1	1.7	1.5	1.9	1.6	2.1	1.8	1.7	2.3	1.6	1.4	1.5	C91
Myeloid leukaemia	2.1	2.1	2.9	2	1.7	1.7	2.3	2.2	2.2	1.9	3	1.9	1.2	C92-94
Leukaemia unspecified	0.5	0.5	0	0.3	0	0.2	0.5	0	0.2	0.2	0.1	0.1	0.5	C95
Myeloproliferative disorders	0.3	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0.5	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	2.6	3	2	3.8	1.5	2.8	2.2	1.8	2.8	2.7	4.2	1.5	2.2	O&U
All sites	105.9	98.9	101	115.1	94.4	101.8	103.1	115.6	122.3	118.8	124.4	127.1	111.4	ALL
All sites but C44	101	94.1	95.8	111.2	91	97.9	100.1	111.3	118.7	115.2	120.8	123.3	108.1	ALLbC44

## Overall Results

**Table 12: Distribution of Cancer Cases in Oman by Nationality**

Nationality	Frequency	Percentage (%)
Total malignancies (Omanis)	1,994	90.7
Adult Omanis	1,868	93.7
Pediatric Omanis	125	6.3
Total malignancies (Non-Omani)	191	8.7
Adult Non-Omanis	185	96.9
Pediatric Non-Omanis	6	3.1
Carcinoma in Situ (Omani)	11	0.5
Carcinoma in Situ (Non-Omani)	2	0.1
<b>Total</b>	<b>2,198</b>	<b>100</b>


The total number of all tumors registered in 2020 was 2,198 (Table 12) , Of these 1,994 (90.76%) were among Omanis, 191 (8.7%) were Non-Omanis, and only 13 (0.6%) cases were carcinoma in Situ. Of the total 1994 males' accounted for 930 cases (46.6%) and females' accounted for 1064 cases (53.4%). The male: female ratio was 1:1.14. In children aged 14 years and below, 125 (6.3%) cases were reported. The median age at diagnosis was 52 years. This was higher in males (median age 58) than in females (median age 49).The most common cancer was breast cancer, and the median age at diagnosis is 47 years.

**Table 13: Distribution of Cancer Cases Among Omanis by Gender**

Gender	Frequency	(%) Percentage	CR	ASR
Male	930	46.6	68.3	109.6
Female	1064	53.4	79.4	111.4
<b>Total</b>	<b>1,994</b>	<b>100</b>	<b>73.8</b>	<b>109.6</b>

In 2020 the crude incidence rate for all cancer among Omanis was 68.3 per 100,000 for males and 79.4 per 100,000 for females. The age-standardized rate, adjusted to the world standard population was 109.6 per 100,000 for males and 111.4 per 100,000 for female.

**Figure 6: Age –Standardized Global Cancer Incidence Rates in Oman and Selected Countries**




Source: World Cancer Research foundation

## Overall Results

### Regional Distribution

The high frequency of cancer reported from Muscat, 544 cases, could be biased since the majority of cancer cases are referred to the National Oncology Center in Muscat, and people sometimes give a local address in Muscat rather than their original place of residence.

**Figure 7: Regional Distribution of incident cases (Frequency & Crude Rate)**



Region	Muscat	North Al Batinah -	Ad - Dakhiliyah	South Al Batinah -	Dhofar	South Ash Sharqiyah -	North Ash - Sharqiyah	Adh Dakhiliyah-	Buraymi	Musandam	Al - Wusta	unknown	Total
Frequency	544	345	221	202	189	135	129	125	41	23	8	32	1994
Incidence	101.4	63.5	61.4	58.1	88.8	60.7	68.2	78.0	57.0	67.9	32.3	73.8	

## Overall Results

**Table 14: Frequency of Incident Cases among Omani Males, 2020**

SITE	ALL AGES	AGE UNK	-0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	+75	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00	
Tongue	10	0	0	0	0	0	0	0	2	1	1	1	1	0	3	0	0	1	1.1	C01-02	
Mouth	15	0	0	0	0	1	0	1	1	3	1	1	1	1	2	1	2	0	1.7	C03-06	
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0.1	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09	
Other oropharynx	4	0	0	0	0	1	0	0	0	0	1	0	0	0	0	2	0	0	0.4	C10	
Nasopharynx	5	0	0	0	0	1	1	0	0	0	0	2	0	0	0	0	0	1	0.6	C11	
Hypopharynx	2	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0.2	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14	
Oesophagus	14	0	0	0	0	0	0	0	1	0	1	2	0	3	1	1	0	5	1.6	C15	
Stomach	45	0	0	0	0	0	0	0	1	1	2	1	1	6	1	7	6	19	5	C16	
Small intestine	7	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	3	2	0.8	C17	
Colon	90	0	0	0	0	2	1	4	3	2	7	8	8	10	14	11	7	13	10	C18	
Rectum	40	0	0	0	0	0	0	1	2	1	3	3	6	3	5	3	4	9	4.5	C19-20	
Anus	4	0	0	0	0	0	0	0	1	0	0	2	1	0	0	0	0	0	0.4	C21	
Liver	42	0	2	0	0	0	0	0	1	0	2	0	5	5	4	8	5	10	4.7	C22	
Gallbladder etc	6	0	0	0	0	0	0	0	0	0	0	2	1	0	0	2	0	1	0.7	C23-24	
Pancreas	17	0	0	0	0	0	0	0	0	0	0	1	3	2	0	2	3	6	1.9	C25	
Nose, sinuses etc	3	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	0.3	C30-31	
Larynx	13	0	0	0	0	0	0	0	0	0	0	1	3	3	1	4	1	0	1.4	C32	
Trachea, bronchus and lung	51	0	0	0	0	0	0	0	1	3	1	0	1	4	8	7	15	11	5.7	C33-34	
Other thoracic organs	3	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0.3	C37-38	
Bone	5	0	0	1	1	2	0	0	0	0	1	0	0	0	0	0	0	0	0.6	C40-41	
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C43	
Other skin	32	0	0	0	0	0	0	0	1	1	1	2	3	0	2	5	2	4	11	3.6	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0.1	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0.1	C46	
Connective and soft tissue	16	0	3	1	0	0	0	1	1	0	3	2	1	0	0	1	1	2	1.8	C47,C49	
Breast	11	0	0	0	0	0	0	0	1	1	0	0	0	2	1	1	5	0	1.2	C50	
Penis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0.2	C60	
Prostate	71	0	0	0	0	0	0	0	0	0	0	0	0	1	9	14	9	9	29	7.9	C61
Testis	21	0	3	1	0	1	3	5	5	1	0	0	0	1	1	0	0	0	2.3	C62	
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63	
Kidney	11	0	1	0	0	0	0	0	1	1	0	0	0	1	1	4	2	0	0	1.2	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	46	0	0	0	0	0	1	0	1	0	2	3	1	7	5	4	4	18	5.1	C67	
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	2	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.2	C69	
Brain, nervous system	40	0	4	4	2	0	4	2	3	2	7	2	2	2	1	3	2	0	4.5	C70-72	
Thyroid	57	0	0	2	1	0	4	6	6	15	7	6	3	1	1	2	3	0	6.3	C73	
Adrenal gland	6	0	6	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.7	C74	
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75	
Hodgkin disease	35	0	1	1	3	2	5	2	6	3	1	6	2	3	0	0	0	0	3.9	C81	
Non-Hodgkin lymphoma	76	0	2	2	1	2	1	3	3	7	7	5	3	9	6	11	2	12	8.5	C82-85,C96	
Immunoproliferative diseases	5	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	3	0	0.6	C88	
Multiple myeloma	23	0	0	0	0	0	0	0	1	1	2	4	1	1	4	1	4	4	2.6	C90	
Lymphoid leukaemia	29	0	10	4	2	4	0	2	3	0	0	0	0	1	1	0	1	1	3.2	C91	
Myeloid leukaemia	35	0	2	2	3	3	2	3	3	1	2	2	1	3	0	3	3	2	3.9	C92-94	
Leukaemia unspecified	14	0	6	4	1	2	0	0	0	0	1	0	0	0	0	0	0	0	1.6	C95	
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0.1	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS	
Other and unspecified	17	0	1	0	0	0	0	0	0	2	0	1	3	2	2	1	2	3	1.9	O&U	
All sites	930	0	43	22	14	21	22	31	51	48	55	59	50	82	87	91	90	164	103.6	ALL	
All sites but C44	898	0	43	22	14	21	22	30	50	47	53	56	50	80	82	89	86	153	100	ALLbc44	

## Overall Results

**Table 15: Frequency of Incident Cases among Omani Females, 2020**

SITE	ALL AGES	AGE UNK	-0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	+75	(%)	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00	
Tongue	9	0	0	0	0	0	0	0	1	0	1	0	0	0	4	2	1	0	0.9	C01-02	
Mouth	6	0	0	0	0	0	0	0	0	1	1	0	0	0	0	1	0	3	0.6	C03-06	
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09	
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0.2	C10
Nasopharynx	5	0	0	0	0	0	1	0	0	0	1	0	1	2	0	0	0	0	0	0.5	C11
Hypopharynx	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	C12-13
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.1	C14
Oesophagus	4	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	0	1	0	0.4	C15
Stomach	28	0	0	0	0	0	0	2	3	1	4	3	1	1	2	4	4	3	2.7	C16	
Small intestine	5	0	0	0	0	0	0	0	1	0	0	1	0	0	1	2	0	0	0	0.5	C17
Colon	78	0	0	0	0	0	0	3	1	4	7	9	13	8	12	8	8	5	7.5	C18	
Rectum	26	0	0	0	0	0	0	0	0	0	4	5	6	5	2	3	0	1	2.5	C19-20	
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21	
Liver	20	0	0	0	0	0	0	0	0	1	0	0	6	1	1	5	3	3	1.9	C22	
Gallbladder etc	6	0	0	0	0	0	0	0	0	0	1	0	0	0	2	0	1	2	0.6	C23-24	
Pancreas	15	0	0	0	0	0	0	0	0	0	1	1	0	3	1	5	1	3	1.4	C25	
Nose, sinuses etc	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0.1	C30-31
Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C32	
Trachea, bronchus and lung	20	0	0	0	0	0	1	0	0	0	1	2	2	1	3	4	2	4	1.9	C33-34	
Other thoracic organs	2	0	0	0	0	1	0	0	0	0	0	0	0	0	0	1	0	0	0.2	C37-38	
Bone	17	0	0	0	2	6	0	2	1	1	1	1	1	1	1	0	1	0	0	1.6	C40-41
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43	
Other skin	28	0	0	0	0	0	1	2	0	0	2	2	3	0	3	4	2	9	2.7	C44	
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	0	0	0.3	C45	
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46	
Connective and soft tissue	8	0	1	0	1	0	1	0	0	1	0	0	1	1	1	0	1	0	0.8	C47,C49	
Breast	266	0	0	0	0	0	3	10	17	43	51	25	29	26	19	16	14	13	25.7	C50	
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0.1	C51	
Vagina	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.1	C52	
Cervix uteri	30	0	0	0	0	0	0	0	2	3	1	1	1	6	3	5	3	1	4	2.9	C53
Corpus uteri	30	0	0	0	0	0	0	0	1	3	2	3	3	2	1	9	3	3	0	2.9	C54
Uterus unspecified	12	0	0	0	0	0	0	0	0	0	0	0	0	7	2	0	0	2	1	1.2	C55
Ovary	35	0	0	1	0	3	1	1	1	2	3	3	3	3	4	2	4	5	2	3.4	C56
Other female genital organs	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C57
Placenta	2	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	0	0	0	0.2	C58
Kidney	16	0	2	1	0	0	0	0	1	3	0	1	3	1	1	1	0	2	1.5	C64	
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66
Bladder	9	0	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	2	3	0.9	C67
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68
Eye	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0.2	C69
Brain, nervous system	48	0	1	5	2	1	0	3	4	2	5	2	10	4	3	3	1	2	4.6	C70-72	
Thyroid	186	0	0	1	1	8	8	30	36	30	16	14	15	10	7	3	4	3	18	C73	
Adrenal gland	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0.2	C74	
Other endocrine	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.1	C75
Hodgkin disease	25	0	0	0	3	4	6	3	3	3	1	0	0	0	0	2	0	0	0	2.4	C81
Non-Hodgkin lymphoma	42	0	2	0	2	1	1	1	3	4	0	1	1	6	7	2	3	8	4.1	C82-85,C96	
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88
Multiple myeloma	12	0	0	0	0	0	0	0	0	1	1	3	1	0	0	4	1	1	1.2	C90	
Lymphoid leukaemia	19	0	7	3	3	1	1	0	0	0	0	3	0	1	0	0	0	0	0	1.8	C91
Myeloid leukaemia	14	0	0	0	1	1	0	1	3	1	2	1	0	2	0	1	0	1	1.4	C92-94	
Leukaemia unspecified	7	0	4	0	0	1	1	1	0	0	0	0	0	0	0	0	0	0	0	0.7	C95
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS
Other and unspecified	18	0	0	0	0	0	0	1	1	0	2	3	3	0	2	2	3	1	1.7	O&U	
All sites	1064	0	19	11	16	29	23	61	83	104	108	84	116	83	89	82	62	66	100	102.7	ALL
All sites but C44	1036	0	19	11	16	29	23	61	83	104	108	84	116	83	89	82	62	66	100	102.7	ALLbC44

## Overall Results

**Table 16: Age-specific Incidence Rates among Omani Males, 2020**

SITE	ALL AGES	AGE UNK	-0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	+75	CRUDE RATE (%)	CUM -0 64	CUM -0 74	ASR	ICD (10th)		
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00		
Tongue	10	0	0	0	0	0	0	0	1.7	1	1.3	2	2.9	0	13.2	0	0	5.2	0.73	1.1	0.11	0.11	C01-02		
Mouth	15	0	0	0	0	0.9	0	0.8	0.8	2.9	1.3	2	2.9	3.4	8.8	6.4	16.5	0	1.1	1.7	0.12	0.23	C03-06		
Salivary glands	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0.07	0.1	0	0	C07-08		
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09		
Other oropharynx	4	0	0	0	0	0.9	0	0	0	0	1.3	0	0	0	0	12.8	0	0	0.29	0.4	0.01	0.08	0.5	C10	
Nasopharynx	5	0	0	0	0	0.9	0.9	0	0	0	0	3.9	0	0	0	0	0	5.2	0.37	0.6	0.03	0.03	0.5	C11	
Hypopharynx	2	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	0	5.2	0.15	0.2	0	0	0.2	C12-13	
Pharynx unspecified	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C14	
Oesophagus	14	0	0	0	0	0	0	0	0.8	0	1.3	3.9	0	10.3	4.4	6.4	0	26	1.03	1.6	0.1	0.14	1.7	C15	
Stomach	45	0	0	0	0	0	0	0	0.8	1	2.6	2	2.9	20.5	4.4	44.9	49.5	98.8	3.3	5	0.17	0.64	5.8	C16	
Small intestine	7	0	0	0	0	0	0	0	0	0	0	0	0	4.4	6.4	24.8	10.4	0.51	0.8	0.02	0.18	1.1	C17		
Colon	90	0	0	0	0	1.8	0.9	3.2	2.5	1.9	9.1	15.7	23.1	34.2	61.5	70.6	57.8	67.6	6.61	10	0.77	1.41	11.8	C18	
Rectum	40	0	0	0	0	0	0	0.8	1.7	1	3.9	5.9	17.3	10.3	22	19.3	33	46.8	2.94	4.5	0.31	0.58	5.1	C19-20	
Anus	4	0	0	0	0	0	0	0	0.8	0	0	3.9	2.9	0	0	0	0	0	0.29	0.4	0.04	0.04	0.4	C21	
Liver	42	0	1	0	0	0	0	0	0.8	0	2.6	0	14.4	17.1	17.6	51.4	41.3	52	3.08	4.7	0.27	0.73	5.8	C22	
Gallbladder etc	6	0	0	0	0	0	0	0	0	0	0	3.9	2.9	0	0	12.8	0	5.2	0.44	0.7	0.03	0.1	0.9	C23-24	
Pancreas	17	0	0	0	0	0	0	0	0	0	0	0	2	8.7	6.8	0	12.8	24.8	31.2	1.25	1.9	0.09	0.28	2.3	C25
Nose, sinuses etc	3	0	0	0	0	0	0	0	0	0	1	0	0	0	4.4	0	8.3	0	0.22	0.3	0.03	0.07	0.4	C30-31	
Larynx	13	0	0	0	0	0	0	0	0	0	0	0	2	8.7	10.3	4.4	25.7	8.3	0	0.95	1.4	0.13	0.3	2.1	C32
Trachea, bronchus and lung	51	0	0	0	0	0	0	0	0.8	2.9	1.3	0	2.9	13.7	35.1	44.9	123.8	57.2	3.74	5.7	0.28	1.13	7.4	C33-34	
Other thoracic organs	3	0	0	0	0	0	0	0	0	0	1	0	0	0	3.4	4.4	0	0	0.22	0.3	0.04	0.04	0.4	C37-38	
Bone	5	0	0	0.5	0.7	1.8	0	0	0	0	1.3	0	0	0	0	0	0	0	0.37	0.6	0.02	0.02	0.4	C40-41	
Melanoma of skin	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.4	0	0	0.07	0.1	0	0.03	0.2	C43	
Other skin	32	0	0	0	0	0	0	0	0.8	0.8	1	2.6	5.9	0	6.8	22	12.8	33	57.2	2.35	3.6	0.2	0.43	4	C44
Mesothelioma	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	6.4	0	0	0.07	0.1	0	0.03	0.2	C45	
Kaposi sarcoma	1	0	0	0	0	0	0	0	0.8	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	0	C46	
Connective and soft tissue	16	0	1.5	0.5	0	0	0	0.8	0.8	0	3.9	3.9	2.9	0	0	6.4	8.3	10.4	1.17	1.8	0.07	0.15	1.5	C47,C49	
Breast	11	0	0	0	0	0	0	0	0.8	1	0	0	0	0	6.8	4.4	6.4	41.3	0	0.81	1.2	0.07	0.3	1.6	C50
Penis	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	10.4	0.15	0.2	0	0	0.2	C60
Prostate	71	0	0	0	0	0	0	0	0	0	0	0	0	2.9	30.8	61.5	57.8	74.3	150.8	5.21	7.9	0.48	1.14	10.1	C61
Testis	21	0	1.5	0.5	0	0.9	2.7	4	4.1	1	0	0	0	0	3.4	4.4	0	0	0	1.54	2.3	0.11	0.11	1.5	C62
Other male genital organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C63	
Kidney	11	0	0.5	0	0	0	0	0	0.8	1	0	0	0	2.9	3.4	17.6	12.8	0	0	0.81	1.2	0.13	0.19	1.5	C64
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	46	0	0	0	0	0	0.9	0	0.8	0	2.6	5.9	2.9	23.9	22	25.7	33	93.6	3.38	5.1	0.29	0.59	5.9	C67	
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.15	0.2	0	0	0.1	C69
Brain, nervous system	40	0	1.9	2.2	1.4	0	3.6	1.6	2.5	1.9	9.1	3.9	5.8	6.8	4.4	19.3	16.5	0	2.94	4.5	0.23	0.4	3.7	C70-72	
Thyroid	57	0	0	1.1	0.7	0	3.6	4.8	5	14.5	9.1	11.8	8.7	3.4	4.4	12.8	24.8	0	4.19	6.3	0.34	0.52	4.9	C73	
Adrenal gland	6	0	2.9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0.44	0.7	0.01	0.01	0.4	C74	
Other endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C75	
Hodgkin disease	35	0	0.5	0.5	2.2	1.8	4.5	1.6	5	2.9	1.3	11.8	5.8	10.3	0	0	0	0	2.57	3.9	0.24	0.24	2.9	C81	
Non-Hodgkin lymphoma	76	0	1	1.1	0.7	1.8	0.9	2.4	2.5	6.8	9.1	9.8	8.7	30.8	26.4	70.6	16.5	62.4	5.58	8.5	0.51	0.94	8.8	-C82	
Immunoproliferative diseases	5	0	0	0	0	0	0	0	0.8	0	1.3	0	0	0	0	0	0	24.8	0	0.37	0.6	0.01	0.13	0.6	C88
Multiple myeloma	23	0	0	0	0	0	0	0	0.8	1	2.6	7.8	2.9	3.4	17.6	6.4	33	20.8	1.69	2.6	0.18	0.38	3	C90	
Lymphoid leukaemia	29	0	4.9	2.2	1.4	3.6	0	1.6	2.5	0	0	0	0	3.4	4.4	0	8.3	5.2	2.13	3.2	0.12	0.16	2.1	C91	
Myeloid leukaemia	35	0	1	1.1	2.2	2.7	1.8	2.4	2.5	1	2.6	3.9	2.9	10.3	0	19.3	24.8	10.4	2.57	3.9	0.17	0.39	3.4	C92-94	
Leukaemia unspecified	14	0	2.9	2.2	0.7	1.8	0	0	0	0	1.3	0	0	0	0	0	0	0	1.03	1.6	0.04	0.04	0.9	C95	
Myeloproliferative disorders	1	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS	
Other and unspecified	17	0	0.5	0	0	0	0	0	0	1.9	0	2	8.7	6.8	8.8	6.4	16.5	15.6	1.25	1.9	0.14	0.26	2.2	O&U	
All sites	930	0	20.9	12	10.1	18.7	19.7	24.9	42.2	46.5	71.7	115.5	144.3	280.3	382.1	584.3	742.9	852.8	68.29	103.6	5.94	12.58	109.6	ALL	
All sites but C44	898	0	20.9	12	10.1	18.7	19.7	24.1	41.4	45.6	69.1	109.7	144.3	273.4	360.2	571.5	709.9	795.6	65.94	100	5.75	12.15	105.6	ALLbC44	

## Overall Results

**Table 17: Age-specific Incidence Rates among Omani Females, 2020**

SITE	ALL AGES	AGE UNK	-0	-5	-10	-15	-20	-25	-30	-35	-40	-45	-50	-55	-60	-65	-70	+75	CRUDE RATE (%)	CUM -0 64	CUM -0 74	ASR	ICD (10th)	
Lip	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C00	
Tongue	9	0	0	0	0	0	0	0	0.8	0	1.3	0	0	0	14.7	10.4	7.2	0	0.67	0.9	0.08	0.17	1.2	
Mouth	6	0	0	0	0	0	0	0	0	1	1.3	0	0	0	0	5.2	0	13.9	0.45	0.6	0.01	0.04	0.6	
Salivary glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C07-08	
Tonsil	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C09	
Other oropharynx	2	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0	7.2	0	0.15	0.2	0.01	0.05	0.3	
Nasopharynx	5	0	0	0	0	0	0.9	0	0	0	1	0	2.1	5.7	0	0	0	0	0.37	0.5	0.05	0.05	0.5	
Hypopharynx	1	0	0	0	0	0	0	0	0	0	0	1.3	0	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	
Pharynx unspecified	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0	0	0.07	0.1	0	0.03	0.2	
Oesophagus	4	0	0	0	0	0	0	0	0	0	1.3	0	0	3.2	0	5.2	0	4.6	0.3	0.4	0.02	0.05	0.5	
Stomach	28	0	0	0	0	0	0	1.6	2.5	1	5.2	6.2	2.8	3.2	7.3	20.7	28.8	13.9	2.09	2.7	0.15	0.4	3.1	
Small intestine	5	0	0	0	0	0	0	0	0.8	0	0	2.1	0	0	3.7	10.4	0	0	0.37	0.5	0.03	0.08	0.6	
Colon	78	0	0	0	0	0	0	2.5	0.8	4	9.1	18.5	36.8	25.8	44	41.4	57.6	23.2	5.82	7.5	0.71	1.2	9.6	
Rectum	26	0	0	0	0	0	0	0	0	0	5.2	10.3	17	16.1	7.3	15.5	0	4.6	1.94	2.5	0.28	0.36	3.3	
Anus	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C21	
Liver	20	0	0	0	0	0	0	0	0	1	0	0	17	3.2	3.7	25.9	21.6	13.9	1.49	1.9	0.12	0.36	2.7	
Gallbladder etc	6	0	0	0	0	0	0	0	0	0	1.3	0	0	0	7.3	0	7.2	9.3	0.45	0.6	0.04	0.08	0.7	
Pancreas	15	0	0	0	0	0	0	0	0	0	1.3	2.1	0	9.7	3.7	25.9	7.2	13.9	1.12	1.4	0.08	0.25	1.9	
Nose, sinuses etc	1	0	0	0	0	0	0	0	0	0	0	0	0	0	3.7	0	0	0	0.07	0.1	0.02	0.02	0.1	
Larynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C32	
Trachea, bronchus and lung	20	0	0	0	0	0	0.9	0	0	0	1.3	4.1	5.7	3.2	11	20.7	14.4	18.6	1.49	1.9	0.13	0.31	2.5	
Other thoracic organs	2	0	0	0	0	0.9	0	0	0	0	0	0	0	0	5.2	0	0	0.15	0.2	0	0.03	0.2		
Bone	17	0	0	0	1.5	5.5	0	1.6	0.8	1	1.3	2.1	2.8	3.2	0	5.2	0	0	1.27	1.6	0.1	0.13	1.5	
Melanoma of skin	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C43	
Other skin	28	0	0	0	0	0	0	0.9	1.6	0	0	2.6	4.1	8.5	0	11	20.7	14.4	41.8	2.09	2.7	0.14	0.32	3.2
Mesothelioma	3	0	0	0	0	0	0	0	0	0	0	2.1	0	0	3.7	5.2	0	0	0.22	0.3	0.03	0.05	0.4	
Kaposi sarcoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C46	
Connective and soft tissue	8	0	0.5	0	0.7	0	0.9	0	0	1	0	0	2.8	3.2	3.7	0	7.2	0	0.6	0.8	0.06	0.1	0.8	
Breast	266	0	0	0	0	0	2.8	8.2	14.4	42.5	66.4	51.4	82.1	83.8	69.7	82.9	100.7	60.3	19.85	25.7	2.11	3.02	27.3	
Vulva	1	0	0	0	0	0	0	0	0	0	0	0	2.8	0	0	0	0	0	0.07	0.1	0.01	0.01	0.1	
Vagina	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0.07	0.1	0	0	C52	
Cervix uteri	30	0	0	0	0	0	0	1.6	2.5	1	1.3	2.1	17	9.7	18.3	15.5	7.2	18.6	2.24	2.9	0.27	0.38	3.5	
Corpus uteri	30	0	0	0	0	0	0	0.8	2.5	2	3.9	6.2	5.7	3.2	33	15.5	21.6	0	2.24	2.9	0.29	0.47	3.6	
Uterus unspecified	12	0	0	0	0	0	0	0	0	0	0	0	19.8	6.4	0	0	14.4	4.6	0.9	1.2	0.13	0.2	1.6	
Ovary	35	0	0	0.6	0	2.8	0.9	0.8	0.8	2	3.9	6.2	8.5	12.9	7.3	20.7	36	9.3	2.61	3.4	0.23	0.52	4	
Other female genital organs	1	0	0	0	0	0.9	0	0	0	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	C57	
Placenta	2	0	0	0	0	0	0	0	0.8	1	0	0	0	0	0	0	0	0	0.15	0.2	0.01	0.01	0.1	
Kidney	16	0	1	0.6	0	0	0	0	0.8	3	0	2.1	8.5	3.2	3.7	5.2	0	9.3	1.19	1.5	0.11	0.14	1.6	
Renal pelvis	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C65	
Ureter	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C66	
Bladder	9	0	0	0	0	0	0	0	0	0	0	0	0	5.7	3.2	3.7	0	14.4	13.9	0.67	0.9	0.06	0.13	1.1
Other urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C68	
Eye	2	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	7.2	0	0.15	0.2	0	0.04	0.2
Brain, nervous system	48	0	0.5	2.8	1.5	0.9	0	2.5	3.4	2	6.5	4.1	28.3	12.9	11	15.5	7.2	9.3	3.58	4.6	0.38	0.5	4.9	
Thyroid	186	0	0	0.6	0.7	7.3	7.4	24.7	30.5	29.6	20.8	28.8	42.5	32.2	25.7	15.5	28.8	13.9	13.88	18	1.25	1.48	15.7	
Adrenal gland	2	0	0.5	0	0	0	0	0	0	0	0	0	0	0	0	5.2	0	0	0.15	0.2	0	0.03	0.2	
Other endocrine	1	0	0	0	0.7	0	0	0	0	0	0	0	0	0	0	0	0	0	0.07	0.1	0	0	C75	
Hodgkin disease	25	0	0	0	2.2	3.7	5.6	2.5	2.5	3	1.3	0	0	0	7.3	0	0	0	1.87	2.4	0.14	0.14	1.9	
Non-Hodgkin lymphoma	42	0	1	0	1.5	0.9	0.9	0.8	2.5	4	0	2.1	2.8	19.3	25.7	10.4	21.6	37.1	3.13	4.1	0.31	0.47	4.4	
Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	C88	
Multiple myeloma	12	0	0	0	0	0	0	0	0	1	1.3	6.2	2.8	0	0	20.7	7.2	4.6	0.9	1.2	0.06	0.2	1.5	
Lymphoid leukaemia	19	0	3.5	1.7	2.2	0.9	0.9	0	0	0	0	0	0	3.2	0	0	0	0	1.42	1.8	0.09	0.09	1.5	
Myeloid leukaemia	14	0	0	0	0.7	0.9	0	0.8	2.5	1	2.6	2.1	0	6.4	0	5.2	0	4.6	1.04	1.4	0.09	0.11	1.2	
Leukaemia unspecified	7	0	2	0	0	0.9	0.9	0.8	0	0	0	0	0	0	0	0	0	0	0.52	0.7	0.02	0.02	0.5	
Myeloproliferative disorders	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MPD	
Myelodysplastic syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	MDS	
Other and unspecified	18	0	0	0	0	0	0	0.8	0.8	0	0	2.6	6.2	8.5	0	7.3	10.4	21.6	4.6	1.34	1.7	0.13	0.29	2.2
All sites	1064	0	9.6	6.2	12	26.6	22.2	51.9	70.3	102.7	143.1	177	337.1	267.6	337.6	445.4	460.5	348.1	79.39	102.7	7.82	12.35	111.4	
All sites but C44	1036	0	9.6	6.2	12	26.6	21.3	50.2	70.3	102.7	140.5	172.9	328.6	267.6	326.6	424.7	446.1	306.3	77.3	100	7.68	12.03	108.1	

## Overall Results


---

### Common Cancers in Omanis

**Table 18: Ten Most Common Cancers among Omanis (Males & Females ) 2019 & 2020**

2019		2020	
Topography	Frequency	Topography	Frequency
Breast	350	Breast	277
Thyroid	235	Thyroid	243
Colorectal	213	Colorectal	234
Stomach	116	Non-Hodgkin lymphoma	118
Prostate	113	Leukaemia	118
Non-Hodgkin lymphoma	93	Brain	88
Leukaemia	91	Stomach	73
Trachea, bronchus and lung	82	Prostate	71
Bladder	76	Trachea, bronchus and lung	71
Liver	68	Skin	61

**Figure 8: Frequency distribution of the common cancers among Omani males and females, 2020**



## Overall Results

### Age specific incidence rate of five common cancer

Figure 9: Age-Specific incidence rates of breast cancer by gender, 2020






Figure 10: Age-Specific incidence rates of thyroid cancer by gender , 2020




## Overall Results

**Figure 11: Age-Specific incidence rates of colorectal cancer by gender, 2020**




**Figure 12: Age-Specific incidence rates of Non Hodgkins Lymphoma by gender, 2020**



## Overall Results

---

Figure 13: Age-Specific incidence rates of Leukemia by gender, 2020



## Overall Results

**Table 19: Ten Most Common Cancers among Omanis**

Male			Female		
Topography	Frequency	Percentage	Topography	Frequency	Percentage
Colorectal	130	14.0	Breast	266	25.00
Leukaemia	78	8.4	Thyroid	186	17.5
Non-Hodgkin lymphoma	76	8.2	Colorectal	104	9.8
Prostate	71	7.6	Brain	48	4.5
Thyroid	57	6.1	Non-Hodgkin lymphoma	42	4
Lung	51	5.5	Uterus	42	4
Bladder	46	4.9	Leukaemia	40	3.8
Stomach	45	4.8	Ovary	35	3.3
Liver	42	4.5	Cervix	30	2.8
Brain	40	4.3	Stomach	28	2.6

**Figure 14: Most Common Cancers in Oman 2020**





Figure 15: Age-specific incidence rates by gender, 2020



## Overall Results

**Table 20: Incident cases by most valid basis of diagnosis among Omanis, 2020**

Site	*A	*B	*C	*D	Total
Lip	0	0	0	0	0
Tongue	0	0	19	0	19
Mouth	0	0	21	0	21
Salivary Glands	0	0	1	0	1
Oropharynx	0	0	6	0	6
Nasopharynx	0	0	10	0	10
Oesophagus	0	0	18	0	18
Stomach	0	0	73	0	73
Colorectum	0	0	234	0	234
Small Intestine	0	0	12	0	12
Liver	0	21	41	0	62
Gall Bladder	0	2	10	0	12
Pancreas	0	4	28	0	32
Nose, Sinuses	0	0	4	0	4
Larynx	0	0	13	0	13
Trachea, Bronchus, Lung	0	1	70	0	71
Bone	0	0	22	0	22
Connective Tissue	0	0	24	0	24
Melanoma	0	0	1	0	1
Skin	0	0	60	0	60
Kaposi's Sarcoma	0	0	1	0	1
Breast	0	0	277	0	277
Cervix uteri	0	0	30	0	30
Uterus	0	0	42	0	42
Ovary	0	0	35	0	35
Vagina	0	0	1	0	1
Prostate	0	0	71	0	71
Testis	0	0	21	0	21
Kidney	0	0	27	0	27
Bladder	0	0	55	0	55
Eye	0	0	4	0	4
Brain, Nervous System	0	0	88	0	88
Thyroid	0	0	243	0	243
Hodgkin's Disease	0	0	60	0	60
Non Hodgkin's Disease	0	0	118	0	118
Plasmacytoma	0	0	35	0	35
Leukemia	0	0	118	0	118
Other and Unspecified	0	1	71	0	72
Total	0	29	1965	0	1994
<b>Percentage of total</b>	<b>0</b>	<b>1.5</b>	<b>98.5</b>	<b>0</b>	<b>100</b>

### Key to basis of diagnosis\*

A = Death certificate only

B = Non-microscopic: clinical, clinical investigation, and specific tumour markers, exploratory surgery without histology


C = Microscopic: cytology, histology of primary, and histology of metastasis

D = Unknown


## Overall Results

---

**Figure 16: The most frequent types of cancer by gender (0-14)**




**Figure 17: The most frequent types of cancer by gender (15-39)**




## Overall Results

---

**Figure 18: The most frequent types of cancer by gender (40-64)**



**Figure 19: The most frequent types of cancer by gender (65+)**



## Overall Results

**Table 21: Top five cancers by Governorate 2019**

Muscat	Breast	Colorectal	Thyroid	Stomach	Prostate
	120	62	57	31	28
North Al - Batinah	Thyroid	Breast	Colorectal	Stomach	Luekemia
	42	36	34	23	18
Ad - Dakhliyah	Breast	Thyroid	Colorectal	Prostate	Luekemia
	49	28	15	15	13
South Al - Batinah	Breast	Thyroid	Stomach	Colorectal	Prostate
	30	27	23	21	14
Dhofar	Breast	Colorectal	Thyroid	Prostate	Non-Hodgkin lymphoma
	30	23	19	13	12
South Ash - Sharqiah	Colorectal	Breast	Thyroid	Stomach	Liver
	24	22	20	10	8
North Ash - Sharqiyah	Breast	Colorectal	Thyroid	Skin	Prostate
	22	16	14	9	9
Adh -Dhahirah	Breast	Thyroid	Colorectal	Prostate	Luekemia
	28	19	13	12	9
Buraymi	Breast	Thyroid	Colorectal	Prostate	Luekemia
	28	19	13	12	9
Musanadam	Breast	Stomach	Thyroid	Non-Hodgkin lymphoma	Skin
	4	3	2	2	2
Al - Wusta	Liver	Thyroid	Non-Hodgkin lymphoma	Breast	Colorectal
	2	2	2	1	1

**Table 22: Top five cancers by Governorate 2020**

Muscat	Breast	Colorectal	Thyroid	Luekemia	Non-Hodgkin lymphoma
	85	73	70	37	26
North Al - Batinah	Breast	Thyroid	Colorectal	Non-Hodgkin lymphoma	Luekemia
	50	40	38	20	19
Ad - Dakhliyah	Thyroid	Breast	Colorectal	Brain	Luekemia
	30	29	26	16	12
South Al - Batinah	Thyroid	Breast	Colorectal	Non-Hodgkin lymphoma	Skin
	29	26	20	14	12
Dhofar	Colorectal	Breast	Luekemia	Non-Hodgkin lymphoma	Stomach
	21	19	19	16	14
South Ash - Sharqiah	Colorectal	Breast	Non-Hodgkin lymphoma	Lung	Thyroid
	18	12	12	9	8
North Ash - Sharqiyah	Breast	Thyroid	Colorectal	Pancreas	Lung
	18	14	12	8	8
Adh -Dhahirah	Breast	Thyroid	Colorectal	Luekemia	Prostate
	32	21	16	7	5
Buraymi	Thyroid	Breast	Tongue	Non-Hodgkin lymphoma	Colorectal
	13	11	3	2	2
Musanadam	Non-Hodgkin lymphoma	Thyroid	Stomach	Breast	Hodgkin lymphoma
	6	3	3	2	2
Al - Wusta	Thyroid	Colorectal	Liver	Lung	Cervix
	2	1	1	1	1




# Cancers by Sites



Table 23: Gender Distribution of Bone Malignancies


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	5	0.4	0.4
Female	17	1.3	1.5
Total	22		

Figure 20: Age-standardized incidence rates of cancer of bone in Oman and some selected countries




Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

Figure 21: Morphology of Bone Cancer




**Figure 22: Incidence of Bone Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	5	0.9
North Al - Batinah	3	0.6
Ad - Dakhliyah	4	1.1
South Al - Batinah	4	1.2
Dhofar	0	0.0
South Ash - Sharqiah	3	1.3
North Ash - Sharqiyah	0	0.0
Adh -Dhahirah	1	0.6
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	1	4.0
Unknown	1	
<b>Total</b>	<b>22</b>	




**Trend of Bone Cancer 1996-2020**



**Table 24: Gender Distribution of Cancer of the Brain & Nervous System**


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	40	2.9	3.7
Female	48	3.6	4.9
Total	88		

**Figure 23: Age-standardized incidence rates of cancer of the Brain and Nervous System in Oman and some selected countries**



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (İzmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

**Figure 24: Morphology of Brain and Nervous System Cancer**






**Figure 25: Incidence of Brain and Nervous System Cancer by Governorates**

(Incidence rates are per 100,000 population)

Governorates	Frequency	Incidence
Muscat	21	3.9
North Al - Batinah	18	3.3
Ad - Dakhliyah	16	4.4
South Al - Batinah	10	2.9
Dhofar	5	2.3
South Ash - Sharqiah	8	3.6
North Ash - Sharqiyah	4	2.1
Adh -Dhahirah	5	3.1
Buraymi	0	0.0
Musandam	1	3.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>88</b>	



**Trend of Brain Cancer 1996-2020**







Table 25: Gender Distribution of Breast Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	11	0.8	1.6
Female	266	19.8	27.3
Total	277		
Carcinoma in situ	9		
Malignant lymphoma	1		

Figure 26: Age-standardized incidence rates of Female Breast Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

Figure 27: Morphology of Breast Cancer




\*Not otherwise specified



**Figure 28: Incidence of Breast Cancer by Governorates**


(Incidence rates are per 100,000 population)



Governorates	Frequency	Incidence
Muscat	85	31.9
North Al - Batinah	50	18.6
Ad - Dakhiliyah	29	16.2
South Al - Batinah	27	15.6
Dhofar	19	18.1
South Ash - Sharqiah	12	10.9
North Ash - Sharqiyah	18	19.1
Adh -Dhahirah	23	28.8
Buraymi	11	31.1
Musandam	2	12.1
Al - Wusta	0	0.0
Unknown	2	
<b>Total</b>	<b>278</b>	



Unknown 2

### Trend of Breast Cancer 1996-2020




**Figure 29: Stages of Breast Cancer 2019****Figure 30: Stages of Breast Cancer 2020**


Stage is based on the American Joint Committee on Cancer 8th edition

**Table 26: Distribution of Cervical Cancer**

Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Female	30	2.2	3.5
Total	30		
Carcinoma in Situ	1		

**Figure 31: Age-standardized incidence rates of Cervical Cancer in Oman and some selected countries**

**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.


**Figure 32: Morphology of Cervical Cancer**

\*Not otherwise specified




**Figure 33: Incidence of Cervical Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	10	3.7
North Al - Batinah	6	2.2
Ad - Dakhliyah	1	0.6
South Al - Batinah	2	1.2
Dhofar	4	3.8
South Ash - Sharqiah	3	2.7
North Ash - Sharqiyah	2	2.1
Adh -Dahirah	0	0.0
Buraymi	1	2.8
Musandam	0	0.0
Al - Wusta	1	8.2
Unknown	0	
<b>Total</b>	<b>30</b>	




### Trend of Cervical Cancer 1996-2020




**Table 27: Gender Distribution of Colorectal Cancer**

Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	130	9.8	17.3
Female	104	7.7	12.9
Total	234		
Malignant lymphoma	2		

**Figure 34: Age-standardized incidence rates of Colorectal Cancer in Oman and some selected countries**

**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

**Figure 35: Morphology of Colorectal Cancer**


\*Not otherwise specified



Figure 36: Incidence of Colorectal Cancer by Governorates

(Incidence rates are per 100,000 population)

Governorates	Frequency	Incidence
Muscat	74	13.8
North Al - Batinah	39	7.2
Ad - Dakhliyah	26	7.2
South Al - Batinah	20	5.8
Dhofar	21	9.9
South Ash - Sharqiah	19	8.5
North Ash - Sharqiyah	12	6.3
Adh -Dhahirah	16	10.0
Buraymi	2	2.8
Musandam	0	0.0
Al - Wusta	1	4.0
Unknown	6	
<b>Total</b>	<b>236</b>	



## Trend of Colorectal Cancer 1996-2020




Figure 37: Stages of Colorectal Cancer 2019





Figure 38: Stages of Colorectal Cancer 2020






**Table 28: Gender Distribution of Esophageal Cancer**


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	14	1.0	1.7
Female	4	0.3	0.5
Total	18		

**Figure 39: Age-standardized incidence rates of Esophageal Cancer in Oman and some selected countries**



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.


**Figure 40: Morphology of Esophageal Cancer**




\*Not otherwise specified

**Figure 41: Incidence of Esophageal Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	4	0.7
North Al - Batinah	3	0.6
Ad - Dakhliyah	2	0.6
South Al - Batinah	1	0.3
Dhofar	4	1.9
South Ash - Sharqiah	1	0.4
North Ash - Sharqiyah	2	1.1
Adh -Dhahirah	1	0.6
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>18</b>	



## Trend of Esophageal Cancer 1996-2020






**Table 29: Gender Distribution of Head and Neck Cancer**


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	37	2.7	4.1
Female	24	1.8	2.9
Total	61		

**Figure 42: Age-standardized incidence rates of Head and Neck Cancer in Oman and some selected countries**



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

**Figure 43: Morphology of Head and Neck Cancer**




\*Not otherwise specified



**Figure 44: Incidence of Head and Neck Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	21	3.9
North Al - Batinah	9	1.7
Ad - Dakhliyah	3	0.8
South Al - Batinah	6	1.7
Dhofar	10	4.7
South Ash - Sharqiah	6	2.7
North Ash - Sharqiyah	0	0.0
Adh -Dhahirah	2	1.2
Buraymi	3	4.2
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	1	
<b>Total</b>	<b>61</b>	



## Trend of Head and Neck Cancer 1996-2020







Table 30: Gender Distribution of Kidney and Ureter Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	11	0.8	1.5
Female	16	1.2	1.6
Total	27		

Figure 45: Age-standardized incidence rates of Kidney and Ureter Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

Figure 46: Morphology of Kidney Cancer




\*Not otherwise specified




**Figure 47: Incidence of Kidney and Ureter Cancer by Governorates**  
 (Incidence rates are per 100,000 population)

Governorates	Frequency	Incidence
Muscat	4	0.7
North Al - Batinah	7	1.3
Ad - Dakhliyah	4	1.1
South Al - Batinah	5	1.4
Dhofar	2	0.9
South Ash - Sharqiah	1	0.4
North Ash - Sharqiyah	2	1.1
Adh -Dhahirah	0	0.0
Buraymi	1	1.4
Musandam	1	3.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>27</b>	




Unknown 0

## Trend of Kidney Cancer 1996-2020




**Table 31: Gender Distribution of Laryngeal Cancer**

Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	13	1.0	2.1
Female	0	0	0
Total	13		

**Figure 48 :Age-standardized incidence rates of Laryngeal Cancer in Oman and some selected countries**

Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

**Figure 49: Morphology of Laryngeal Cancer**


\*Not otherwise specified




**Figure 50: Incidence of Laryngeal Cancer by Governorates**

(Incidence rates are per 100,000 population)

Governorates	Frequency	Incidence
Muscat	2	0.4
North Al - Batinah	2	0.4
Ad - Dakhliyah	3	0.8
South Al - Batinah	0	0.0
Dhofar	1	0.5
South Ash - Sharqiah	2	0.9
North Ash - Sharqiyah	2	1.1
Adh -Dhahirah	1	0.6
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>13</b>	




**Trend of Laryngeal Cancer 1996-2020**



**Table 32: Gender Distribution of Leukemia**


Gender	Frequency	Crude Incidence rate	Age- Standardized incidence rate
Male	78	5.7	6.4
Female	40	2.9	3.2
Total	118		

**Figure 51: Age-standardized incidence rates of Leukemia in Oman and some selected countries**




**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries from 2003-2007 was used.

**Figure 52: Morphology of Leukemia**




**Figure 53 : Incidence of Leukemia by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	37	6.9
North Al - Batinah	19	3.5
Ad - Dakhliyah	12	3.1
South Al - Batinah	7	2.0
Dhofar	19	8.9
South Ash - Sharqiah	8	3.6
North Ash - Sharqiyah	7	3.7
Adh -Dhahirah	7	4.4
Buraymi	1	1.4
Musandam	1	3.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>118</b>	




## Trend of Leukemia Cancer 1996-2020




**Table 33: Gender Distribution of Liver Cancer**

Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	42	3.1	5.8
Female	20	1.5	2.7
Total	62		

**Figure 54: Age-standardized incidence rates of cancer of liver in Oman and some selected countries**

**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK England (Türkiye Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries from 2003-2007 was used .

**Figure 55 : Morphology of Liver Cancer**


\*Not otherwise specified




Figure 56: Incidence of Liver Cancer by Governorates

(Incidence rates are per 100,000 population)

Governorates	Frequency	Incidence
Muscat	19	3.5
North Al - Batinah	13	2.4
Ad - Dakhliyah	6	1.7
South Al - Batinah	3	0.9
Dhofar	6	2.8
South Ash - Sharqiah	3	1.3
North Ash - Sharqiyah	6	3.2
Adh -Dahirah	2	1.2
Buraymi	0	0.0
Musandam	1	3.0
Al - Wusta	1	4.0
Unknown	2	
<b>Total</b>	<b>62</b>	



## Trend of Liver Cancer 1996-2020






**Table 34: Gender Distribution of lymphomas**


Gender	Hodgkin Lymphoma			Non-Hodgkin Lymphoma		
	Frequency	Crude Incidence rate	ASR	Frequency	Crude Incidence rate	ASR
Male	35	2.6	2.9	76	5.6	8.8
Female	25	1.9	1.9	42	3.1	4.4
Total	60			118		

**Figure 57: Age-standardized incidence rates of Hodgkin Lymphoma in Oman and some selected countries**




**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK England Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries from 2003-2007 was used

**Figure 58: Age-standardized incidence rates of Non-Hodgkin Lymphoma in Oman and some selected countries**




**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England ) Türkiye (Izmir) are from 2003-2007, For USA –NPCR , National Program of Cancer Registries from 2003-2007 was used

**Figure 59: Morphology of Hodgkin Lymphoma**




\*Not otherwise specified

**Figure 60: Morphology of Non-Hodgkin Lymphoma**



\*Not otherwise specified


**Figure 61: Distribution of Non-Hodgkin Lymphoma sites**




\*Extranodal site includes: Stomach, Cecum, Bone marrow, Tonsils , Lung, Breast, Liver, Skin , Small intestine

**Figure 62: Incidence of Hodgkin Lymphoma by Governorates  
(Incidence rate are per 100,000 population )**

Governorates	Frequency	Incidence
Muscat	9	1.7
North Al - Batinah	9	1.7
Ad - Dakhliyah	12	3.3
South Al - Batinah	7	2.0
Dhofar	13	6.1
South Ash - Sharqiah	2	0.9
North Ash - Sharqiyah	2	1.1
Adh -Dhahirah	3	1.9
Buraymi	0	0.0
Musandam	2	5.9
Al - Wusta	1	4.0
Unknown	0	
<b>Total</b>	<b>60</b>	




### Trend of Hodgkins Lymphoma Cancer 1996-2020



**Figure 63: Incidence of Non-Hodgkin Lymphoma by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	26	4.8
North Al - Batinah	20	3.7
Ad - Dakhliyah	8	2.2
South Al - Batinah	14	4.0
Dhofar	16	7.5
South Ash - Sharqiah	12	5.4
North Ash - Sharqiyah	5	2.6
Adh -Dhahirah	4	2.5
Buraymi	2	2.8
Musandam	6	17.7
Al - Wusta	0	0.0
Unknown	5	
<b>Total</b>	<b>118</b>	



### Trend of Non-Hodgkins Lymphoma 1996-2020







Table 35: Distribution of Ovarian Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Female	35	2.6	4.0
Total	35		

Figure 64: Age-standardized incidence rates of Ovarian Cancer in Oman and some selected countries



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used

Figure 65: Morphology of Ovarian Cancer




\*Not otherwise specified



**Figure 66: Incidence of Ovarian Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	8	3.0
North Al - Batinah	9	3.3
Ad - Dakhliyah	4	2.2
South Al - Batinah	4	2.3
Dhofar	4	3.8
South Ash - Sharqiah	1	0.9
North Ash - Sharqiyah	1	1.1
Adh -Dhahirah	4	5.0
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>35</b>	



Unknown 0

## Trend of Ovarian Cancer 1996-2020







Table 36: Gender Distribution of Pancreatic Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	17	1.2	2.3
Female	15	1.1	1.9
Total	32		

Figure 67 :Age-standardized incidence rates of Pancreatic Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK(England) Türkiye ( Izmir ) are – from 2003-2007, For USA (NPCR )National Program of Cancer Registries from 2003-2007 was used


Figure 68: Morphology of Pancreatic Cancer



\*Not otherwise specified

**Figure 69 :Incidence of Pancreatic Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	7	1.3
North Al - Batinah	6	1.1
Ad - Dakhliyah	2	0.6
South Al - Batinah	4	1.2
Dhofar	0	0.0
South Ash - Sharqiah	1	0.4
North Ash - Sharqiyah	8	4.2
Adh -Dhahirah	2	1.2
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	2	
<b>Total</b>	<b>32</b>	



Unknown 2

### Trend of Pancreatic Cancer 1996-2020







Table 37: Distribution of Prostate Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	71	5.2	10.1
Total	71		

Figure 70 :Age-standardized incidence rates of Prostate Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries) from 2003-2007 was used


Figure 71:Morphology of Prostate Cancer




\*Not otherwise specified

**Figure 72: Incidence of Prostate Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	20	7.4
North Al - Batinah	10	3.6
Ad - Dakhliyah	9	5.0
South Al - Batinah	8	4.6
Dhofar	4	3.7
South Ash - Sharqiah	6	5.3
North Ash - Sharqiyah	6	6.3
Adh -Dahahirah	5	6.2
Buraymi	1	2.7
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	2	
<b>Total</b>	<b>71</b>	




## Trend of Prostate Cancer 1996-2020




**Table 38: Gender Distribution of Skin Cancer including Melanoma**

Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	35	2.5	4.2
Female	29	2.1	3.2
Total	64		
Kaposi sarcoma	1	0.1	0.0

**Figure 73: Age-standardized incidence rates of Skin Cancer in Oman and some selected countries**


**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used .

**Figure 74 : Morphology of Skin Cancer**



**Figure 75: Incidence of Skin Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	13	2.4
North Al - Batinah	7	1.3
Ad - Dakhliyah	9	2.5
South Al - Batinah	12	3.5
Dhofar	5	2.3
South Ash - Sharqiah	4	1.8
North Ash - Sharqiyah	6	3.2
Adh -Dhahirah	5	3.1
Buraymi	1	1.4
Musandam	1	3.0
Al - Wusta	0	0.0
Unknown	1	
<b>Total</b>	<b>64</b>	



### Trend of Skin Cancer 1996-2020







Table 39: Gender Distribution of Stomach Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	45	3.3	5.8
Female	28	2.1	3.1
Total	73		
Malignant lymphoma	14		

Figure 76 : Age-standardized incidence rates of Stomach Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK England, Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries) from 2003-2007

Figure 77:Morphology of Stomach Cancer




\* Not otherwise specified

## Stomach



## **Stomach Cancers**

**Figure 78 :Incidence of Stomach Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**



## Unknown 2

## Trend of Stomach Cancer 1996-2020







Table 40: Gender Distribution of Thyroid Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	57	4.2	4.9
Female	186	13.9	15.7
Total	243		

Figure 79: Age-standardized incidence rates of Thyroid Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR (National Program of Cancer Registries ) from 2003-2007 was used.

Figure 80: Morphology of Thyroid Cancer




\*Not otherwise specified




**Figure 81: Incidence of Thyroid Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	70	13.1
North Al - Batinah	40	7.4
Ad - Dakhliyah	30	8.3
South Al - Batinah	29	8.3
Dhofar	11	5.2
South Ash - Sharqiah	8	3.6
North Ash - Sharqiyah	14	7.4
Adh -Dhahirah	21	13.1
Buraymi	13	18.1
Musandam	3	8.9
Al - Wusta	2	8.1
Unknown	2	
<b>Total</b>	<b>243</b>	



Unknown 2


## Trend of Thyroid Cancer 1996-2020



**Table 41: Gender Distribution of TBL Cancer**


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	51	3.7	7.4
Female	20	1.5	2.5
Total	71		

**Figure 82 :Age-standardized incidence rates of Trachea, Bronchus and Lung Cancer in Oman and some selected countries**



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR National Program of Cancer Registries from 2003-2007 was used


**Figure 83: Morphology of Trachea, Bronchus and Lung Cancer**





**Figure 84: Incidence of Lung Cancer by Governorates  
(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	22	4.1
North Al - Batinah	6	1.1
Ad - Dakhliyah	7	1.9
South Al - Batinah	5	1.4
Dhofar	7	3.3
South Ash - Sharqiah	9	4.0
North Ash - Sharqiyah	8	4.2
Adh -Dhahirah	3	1.9
Buraymi	1	1.4
Musandam	0	0.0
Al - Wusta	1	4.0
Unknown	2	
<b>Total</b>	<b>71</b>	



Unknown 2

## Trend of Lung Cancer 1996-2020




Figure 85: Stages of lung cancer 2019





Figure 86: Stages of lung cancer 2020






**Table 42: Gender Distribution of Urinary Bladder Cancer**


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Male	46	3.4	5.9
Female	9	0.7	1.1
Total	55		

**Figure 87 :Age-standardized incidence rates of Urinary Bladder Cancer in Oman and some selected countries**



**Note:** Data of GCC countries are from 2008-2012; data of New Zealand, UK (England), Türkiye (Izmir) are from 2003-2007, For USA –NPCR National Program of Cancer Registries from 2003-2007 was used

**Figure 88 :Morphology of Urinary Bladder Cancer**




\*Not otherwise specified



**Figure 89: Incidence of Urinary Bladder Cancer by Governorates**  
**(Incidence rates are per 100,000 population)**

Governorates	Frequency	Incidence
Muscat	13	2.4
North Al - Batinah	7	1.3
Ad - Dakhliyah	8	2.2
South Al - Batinah	9	2.6
Dhofar	5	2.3
South Ash - Sharqiah	3	1.3
North Ash - Sharqiyah	6	3.2
Adh -Dahirah	2	1.2
Buraymi	0	0.0
Musandam	1	3.0
Al - Wusta	0	0.0
Unknown	1	
<b>Total</b>	<b>55</b>	



## Trend of Urinary Bladder Cancer 1996-2020







Table 43: Distribution of Uterine Cancer


Gender	Frequency	Crude Incidence rate	Age standardized incidence rate
Female	42	3.1	5.2
Total	42		

Figure 90: Age-standardized incidence rates of Uterine Cancer in Oman and some selected countries



Note: Data of GCC countries are from 2008-2012; data of New Zealand, UK England, Türkiye (Izmir ) are from 2003-2007, For USA –NPCR National Program of Cancer Registries from 2003-2007 was used

Figure 91: Morphology of Uterine Cancer




\*Not otherwise specified




Figure 92: Incidence of Uterine Cancer by Governorates

Incidence rates are ( per 100,000 population)

Governorates	Frequency	Incidence
Muscat	18	16.7
North Al - Batinah	9	3.3
Ad - Dakhliyah	1	0.6
South Al - Batinah	2	1.2
Dhofar	4	3.8
South Ash - Sharqiah	5	4.5
North Ash - Sharqiyah	0	0.0
Adh -Dhahirah	3	3.8
Buraymi	0	0.0
Musandam	0	0.0
Al - Wusta	0	0.0
Unknown	0	
<b>Total</b>	<b>42</b>	



Trend of Uterine Cancer 1996-2020



# Childhood Cancers

## Childhood Cancers

### Childhood Cancers

Of the 1994 cases reported in Omanis during 2020 , 125 cases were among children aged 14 years and below constituting 6.3% of the total cancers reported.

**Table 44: Frequency of Five Common Cancers in Omani Children**

Topography	Frequency	Percentage (%)
Lymphoid leukemias	29	23.2
Unspecified and other specified leukemias	16	12.8
Neuroblastoma and ganglioneuroblastoma	9	7.2
Hodgkin Lymphomas	8	6.4
Non-Hodgkin lymphomas	7	5.6


**Table 45: Frequency of Five Common Cancers in Omani Boys**

Topography	Frequency	Percentage (%)
Lymphoid leukemias	16	20.2
Unspecified and other specified leukemias	12	26.1
Neuroblastoma and ganglioneuroblastoma	8	17.4
Hodgkin Lymphomas	5	10.9
Acute myeloid leukemias	5	10.9

**Table 46: Frequency of Five Common Cancers in Omani Girls**

Topography	Frequency	Percentage (%)
Lymphoid leukemias	13	28.3
Unspecified and other specified leukemias	4	8.7
Non-Hodgkin lymphomas	3	6.5
Hodgkin Lymphomas	3	6.5
Nephroblastoma and other nonepithelial renal tumors	3	6.5

**Figure 93: Frequency Distribution of Common Cancers in Omani Children  
2020**



**Table 47 : Frequency Distribution of Childhood Cancers in Oman, 2020 (International Classification of Childhood Cancer)**

CR, Crude incidence rate; ASR, Age-Standardized incidence rate. Both rates are per million per year. The above analysis is restricted to children aged 0-14 years

Site	Male						Female					
	-0	-5	-10	All	CR*	ASR*	-0	-5	-10	All	CR*	ASR*
Leukemia, myeloproliferative and myelodysplastic diseases	18	10	6	34	64.4	37.9	11	3	4	18	35.4	22.2
Lymphoid leukemias	10	4	2	16	30.3	17.8	7	3	3	13	25.6	16.8
Acute myeloid leukemias	0	2	3	5	9.5	5.6	0	0	1	1	2.0	1.3
Chronic myeloproliferative diseases	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Myelodysplastic syndrome and other myeloproliferative diseases	1	0	0	1	1.9	1.1	0	0	0	0	0.0	0.0
Unspecified and other specified leukemias	7	4	1	12	22.7	13.4	4	0	0	4	7.9	5.2
<hr/>												
Lymphomas and reticuloendothelial neoplasms	3	3	4	10	19.0	11.1	2	0	5	7	13.8	9.0
Hodgkin lymphomas	1	1	3	5	9.5	5.6	0	0	3	3	5.9	3.9
Non-Hodgkin lymphomas	2	2	0	4	7.6	4.5	1	0	2	3	5.9	3.9
Burkitt lymphoma	0	0	1	1	1.9	1.1	1	0	0	1	2.0	1.3
Miscellaneous lymphoreticular neoplasms	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Unspecified lymphomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
<hr/>												
CNS and miscellaneous intracranial and intraspinal neoplasms	4	3	1	8	15.2	8.9	1	5	2	8	15.7	10.3
Ependymoma and choroids plexus tumours	1	0	0	1	1.9	1.1	0	1	0	1	2.0	1.3
Astrocytomas	1	2		3	5.7	3.3	0	1	1	2	3.9	2.6
Intracranial and intraspinal embryonal tumours	0	0	1	1	1.9	1.1	0	2	1	3	5.9	3.9
Other gliomas	0	1	0	1	1.9	1.1	1	0	0	1	2.0	1.3
Other specified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Unspecified	2	0	0	2	3.8	2.2	0	1	0	1	2.0	1.3
<hr/>												
Neuroblastoma and other peripheral nervous cell tumours	8	0	0	8	15.2	8.9	1	0	0	1	2.0	1.3
Neuroblastoma and ganglioneuroblastoma	8	0	0	8	15.2	8.9	1	0	0	1	2.0	1.3
Other peripheral nervous cell tumours	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
<hr/>												
Retinoblastoma	2	0	0	2	3.8	2.2	1	0	0	1	2.0	1.3
Retinoblastoma	2	0	0	2	3.8	2.2	1	0	0	1	2.0	1.3
<hr/>												
Renal tumours	1	0	0	1	1.9	1.1	2	1	0	3	5.9	3.9
Nephroblastoma and other nonepithelial renal tumors	1	0	0	1	1.9	1.1	2	1	0	3	5.9	3.9
Renal carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
<hr/>												
Hepatic tumours	2	0	2	0	3.8	2.2	0	0	0	0	0.0	0.0

Site	Male						Female					
Hepatoblastoma	2	0	0	2	3.8	2.2	0	0	0	0	0.0	0.0
Hepatic carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Malignant bone tumours	0	0	0	0	0.0	0.0	0	0	2	2	3.9	2.6
Osteosarcomas	0	0	0	0	0.0	0.0	0	0	1	1	2.0	1.3
Chondrosarcomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Ewing tumour and related sarcomas of bone	0	0	0	0	0.0	0.0	0	0	1	1	2.0	1.3
Other specified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Soft tissue and other extraosseous sarcomas	1	3	1	5	9.5	5.6	1	0	0	1	2.0	1.3
Rhabdomyosarcomas	0	1	0	1	1.9	1.1	1	0	0	1	2.0	1.3
Fibrosarcomas, peripheral nerve sheath and other fibrous neoplasms	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Kaposi's sarcoma	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Other specified	1	1	1	3	5.7	3.3	0	0	0	0	0.0	0.0
Unspecified	0	1	0	1	1.9	1.1	0	0	0	0	0.0	0.0
Germ cell and trophoblastic tumours and gonadal neoplasms	4	1	1	6	11.4	6.7	0	1	1	2	3.9	2.6
Intracranial and intraspinal germ cell tumours	0	0	1	1	1.9	1.1	0	0	1	1	2.0	1.3
Malignant extra cranial and extra gonadal germ cell tumours	1	0	0	1	1.9	1.1	0	0	0	0	0.0	0.0
Malignant gonadal germ cell tumours	3	1	0	4	7.6	4.5	0	1	0	1	2.0	1.3
Gonadal carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Other and unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Other malignant epithelial neoplasms and malignant melanomas	0	2	1	3	5.7	3.3	0	1	1	2	3.9	2.6
Adrenocortical carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Thyroid carcinomas	0	2	1	3	5.7	3.3	0	1	1	2	3.9	2.6
Nasopharyngeal carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Malignant melanoma	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Skin carcinomas	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Other and unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
Other and unspecified malignant neoplasms	0	0	0	0	0.0	0.0	0	0	1	1	2.0	1.3
Other specified	0	0	0	0	0.0	0.0	0	0	1	1	2.0	1.3
Other unspecified	0	0	0	0	0.0	0.0	0	0	0	0	0.0	0.0
<b>Total</b>	<b>43</b>	<b>22</b>	<b>14</b>	<b>79</b>	<b>149.7</b>	<b>88.0</b>	<b>19</b>	<b>11</b>	<b>16</b>	<b>46</b>	<b>90.4</b>	<b>59.4</b>

# Cancer among Non-Omanis

## Cancer among Non-Omanis

### Cancer among Non-Omanis

The total number of all tumors registered among Non-Omanis was 193. Of these only 2 cases (1%) were carcinoma in Situ. Out of 191 malignant cases males accounted for 97 case (50.8%) and females accounted for 94 cases (49.2%) as shown in (Table 48).The median age at diagnosis was 49 years. This was higher in females (median age 50) than in males (median age 47). The highest frequency of cancers in non-nationals were reported in Muscat (130 cases) followed by Dhofar (30 cases).

**Table 48: Gender Distribution of cancer cases among Non-Omanis**

Gender	Frequency	Percentage (%)
Male	97	50.8
Female	94	49.2
<b>Total</b>	<b>191</b>	<b>100</b>
Carcinoma in situ	2	

**Table 49: Five Most Common Cancers in Non-Omanis (Males & Females)**

Topography	Frequency	Percentage (%)
Breast	48	25.1
Leukemia	20	10.5
Colorectal	16	8.4
stomach	10	5.2
Tongue	7	3.7

**Table 50: Five Most Common Cancers in Non-Omanis (Males)**


Topography	Frequency	Percentage (%)
Leukemia	15	15.5
Colorectal	9	9.3
Stomach	7	7.2
Prostate	5	5.2
Testis	5	5.2

## Cancer among Non-Omanis


**Table 51: Five Most Common Cancers among Non-Omanis (Females)**

Topography	Frequency	Percentage (%)
Breast	47	50
Colorectal	7	7.4
Ovary	7	7.4
Thyroid	6	6.4
Leukemia	5	5.3

**Figure 94: Stages of breast cancer 2019**



**Figure 95: Stages of breast cancer 2020**



## Cancer among Non-Omanis

**Table 52: Regional Distribution of Cancer Cases among Non-Omanis**

Region	Frequency
Muscat	103
Dhofar	30
North Al Batinah	20
Al Buraymi	3
North Ash Sharqiyah	7
Ad Dakhliyah	9
South Ash Sharqiyah	3
South Al Batinah	4
Adh Dhahirah	3
Musandam	5
AL Wusta	3
Unknown	1
<b>Total</b>	<b>191</b>


Country	Frequency
Iran, Islamic Republic of	3
Lebanon	2
Sri Lanka	1
Afghanistan	1
Algeria	1
Colombia	1
Monaco	1
Bahrain	1
Canada	1
Poland	1
Romania	1
Ukraine	1
United States of America	1
Morocco	2
New Zealand	1
Unknown	4
<b>Total</b>	<b>191</b>

**Table 53: Distribution of Cancer Cases among Non-Omanis by Nationality 2020**

Country	Frequency
India	34
Egypt	20
Bangladesh	19
Sudan	11
United Republic of Tanzania	9
United Kingdom	6
Philippines	16
Pakistan	16
Yemen	15
Iraq	6
Syrian Arab Republic	6
Jordan	5
Tunisia	4

## Deaths Due to Cancer

**Figure 96 : Most Common Causes of MOH Hospital Deaths  
(Source: Annual Health Report 2020)**



## **Annex 1**

**Oman National Cancer Registry  
Directorate General of Primary Health Care  
Ministry of Health  
Sultanate of Oman**

**Request for Data from the Oman National Cancer Registry  
All requests should be submitted to the attention of the Director,  
Department of Non-Communicable Disease**

DGPHC, Post Box 393, Area Code 100, Muscat, Sultanate of Oman  
Tel: (968) 24946378                                  Fax: (968) 24946379

Date Submitted :

Name :

Department :

Institution :

Telephone No :                                  Fax No :

**Information Requested:**

(Specify patient population, Time period, Year/s, Anatomic site/Histology, Region / Wilayat etc.)

**Purpose of Request:**

(Specify presentation at conference/meeting/publication, clinical/epidemiological study, personal information, etc.)

**Collaborators and Co-authors:**

**Ethical approval received..... : Yes / No**

**Requester's affirmation statement:**

I hereby, the requester of the above data affirm that the data given to me by the Oman National Cancer Registry will be treated with utmost confidentiality in relation to patient's identity, I also affirm that the data given to me will not be presented or published by me or any of my collaborators as an original work but rather can be cited in my presentation and / or publication with acknowledgement to the ONCR.

Requester's signature :

Date :

**For official use only:**

Request :

Approved :

Denied :

Director of Non- Communicable Disease department Signature  
Date :



## Annex 2



### SAMPLE OF OMAN NATIONAL CANCER REGISTRY FORM

To : Directorate General of Health Affairs Department of Non-Communicable Disease Surveillance & Control (DNCD)								DGHA, Muscat Tel: 24696187, Fax : 24695480 E-mail : dep-ncd@moh.gov.om											
1. Cancer Registry No. (To be filled by the Cancer Registry) <input type="text"/>								2. Date of Registration (To be filled by the Cancer Registry) <input type="text"/>											
3. Patient Hospital File No. <input type="text"/>								4. Hospital Name <input type="text"/>											
5. Department of <input type="text"/>								6. Civil ID. <input type="text"/>											
7. First Name				8. Father's Name				9. Grandfather's Name				10. Tribe Name							
11. Sex <input type="checkbox"/> 1=M <input type="checkbox"/> 2=F <input type="checkbox"/> 3=Unknown				12. Marital Status <input type="checkbox"/> 1=Single <input type="checkbox"/> 2=Married <input type="checkbox"/> 3=Divorced <input type="checkbox"/> 4=Widowed <input type="checkbox"/> 5=Unknown				13. Age or D. of Birth <input type="text"/> D D M M Y Y Y Y				14. Nationality 1= Omani 2= Non-Omani (Specify) _____ 3= Unknown							
15. Country of Birth <input type="text"/>				16. Religion <input type="checkbox"/> 1= Muslim, 2= Christian <input type="checkbox"/> 3= Hindu, 4= Jewish <input type="checkbox"/> 5= Others, 9= Not Known				17. Ethnic Group <input type="checkbox"/> 1= Arab <input type="checkbox"/> 3= Caucasian <input type="checkbox"/> 4= Other <input type="checkbox"/> 9= Not Known				18. Occupation <input type="text"/>							
<b>Patient's Address</b>																			
19. Telephone Land Line <input type="text"/>				21. Wilayat : <input type="text"/>															
Mobile <input type="text"/>				22. Village : <input type="text"/>															
20. Other contact's Tel. No. <input type="text"/>				23. Date of First Diagnosis <input type="text"/> D D M M Y Y Y Y				24. If Pt had Biopsy give Lab. Biopsy Specimen No. <input type="text"/>				ICD-0-3 Code <input type="text"/>							
<b>25. Primary Site of Cancer.....</b>																			
(ICD-0-3 Code will be filled by the Central Registry)																			
27. Laterality <input type="checkbox"/> 0=Not a Paired Site, Unknown or ill-defined Site 1=Right : Origin of Primary 2=Left : Origin of Primary 3=Bilateral Involvement 9=Paired Site, Laterality Unknown				28. Extent of Disease <input type="checkbox"/> 0=in Situ 1=Localized 2=Regional by Direct Extension 3=Regional to Lymph Nodes 4=Regional, (both 2,3) 5=Regional, (not specified) 7=Distant Metastasis/Systemic Disease 8=Not applicable (e.g. Leukemias) 9=Unstaged, Unknown or Unspecified				29. Histologic Grading <input type="checkbox"/> 1=Grade I Well differentiated/Differentiated, NOS 2=Grade II Moderately differentiated/Moderately well differentiated/ Intermediate differentiation. 3=Grade III Poorly differentiated 4=Grade IV Undifferentiated anaplastic 5=T - Cell 6=B. Cell 7=Null Cell 8=Killer Cell 9=Grade or differentiation not determined, not stated or not applicable 10=Other's											
TNM Classification 30. T <input type="text"/> Tx To Tis Tmic T1 T2 T3 T4				31. N <input type="text"/> Nx N0 N1 N2 N3				32. M <input type="text"/> Mx M0 M1				33. M <input type="checkbox"/> Not applicable							
34. Clinical (Stage) I Ia Ib Ic II IIa IIb IIc III IIIa IIIb IV IVa IVb IVc IVd		99= UnKnown, Un-Specified, Not Applicable																	
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17		99																	
35. Most valid basis of Diagnosis <input type="checkbox"/>								36. Treatment <input type="checkbox"/> 1=Surgery <input type="checkbox"/> 2=Radiotherapy <input type="checkbox"/> 3=Chemotherapy <input type="checkbox"/> 4=Hormonal Therapy <input type="checkbox"/> 5=Immunotherapy <input type="checkbox"/> 6=Bone Marrow Transplant								7=Neoadjuvant 8=Supportive/palliative 9=Other Treatment 10=Not Known 11=Y 2=N			
Non-Microscopic 0=Death certificate only 1=Clinical only 2=Clinical investigation (e.g. X-ray, Isotope) 3=Exploration surgery but without Histology 4=Specific Biochemical and/or immunological tests								Microscopic 5=Cytological/Haematology 6=Histology of primary 7=Histology of Metastasis 8=Autopsy 9=Not known											
37. Date of Death <input type="text"/> D D M M Y Y Y Y								38. Cause of Death <input type="checkbox"/> 1=Cancer or Cancer related 2=Unrelated to Cancer 3=Not known											
39. Date of Last Contact <input type="text"/> D D M M Y Y Y Y								Doctor's Name : _____											
40. Source of information <input type="checkbox"/> 1 = Medical File   2 = Death Certificate   3 = Other   9 = Unknown								Doctor's Designation : _____											
Doctor's Signature : _____								Department : _____											
Date : _____								Tumor Registrar : _____ ( To be Filled by the Cancer Registry ) Coding : _____ Entry : _____											

1. Send White copy to NCD Section Fax : 24695480 2. Keep Pink Copy in Patient's Case Notes (File) 3. Send Blue Copy to Medical Records Dept.

MR-123

### Annex 3

## Electronic Notification Form of Cancer in Al Shifa System

Cancer Registry

Governorate <input type="button" value="Select"/>	Wilayat <input type="button" value="Select"/>	Institution* <input type="button" value="Select"/>	Reporting Date <input type="text"/>			
<b>Patient Information</b> <span style="float: right;">[Enter Card Expiry date if you have Identity card otherwise enter date of birth]</span>						
Patient Id * <input type="text"/>	Civil Id <input type="text"/>	Expiry Date <input type="text"/> DD-MM-YYYY	DOB * <input type="text"/> DD-MM-YYYY	Age <input type="text"/> Years <input type="button" value=""/>	Passport No <input type="text"/>	Nationality * <input type="button" value="Select"/>
First Name* <input type="text"/>	Second Name <input type="text"/>	Third Name <input type="text"/>	Tribe <input type="text"/>	Sheikh Name <input type="text"/>	Gender <input type="button" value=""/>	
Mobile No <input type="text"/>	Next of Kin Mobile No <input type="text"/>	Marital Status <input type="button" value=""/>	Education <input type="button" value=""/>	Work Status <input type="button" value=""/>	Occupations* <input type="button" value=""/>	
Place of work* <input type="text"/>	Monthly Income <input type="text"/>	Governorate * <input type="button" value="Select"/>	Wilayat * <input type="button" value="Select"/>	Village * <input type="button" value="Select"/>	Latitude <input type="text"/>	
Longitude <input type="text"/>						
<b>Cancer Registry Details</b>						
Ethnic Group <input type="button" value=""/>	Behavior <input type="button" value=""/>	First Diagnosis Date <input type="text"/>	Laterality <input type="button" value=""/>	Extent Of Disease <input type="button" value=""/>		
Primary Site Cancer <input type="text"/>			Biopsy Specimen No. <input type="text"/>			
Histological Type <input type="text"/> Please select primary site cancer first			Histologic Grading <input type="text"/>			
<b>TNM Classification (Clinical)</b>						
T Classification <input type="button" value=""/>	N Classification <input type="button" value=""/>	M Classification <input type="button" value=""/>	Clinical Stage. <input type="button" value=""/>	Basis Of Diagnosis <input type="button" value=""/>		
Treatment Name <input type="text"/>		Remarks <input type="text"/>				
<input type="checkbox"/> Bone Marrow Transplant <input type="checkbox"/> Chemotherapy <input type="checkbox"/> Hormonal therapy <input type="checkbox"/> Immunotherapy <input type="checkbox"/> Not Known <input type="checkbox"/> Other Treatment						
Patient Status <input type="button" value=""/>	Last Contact Date <input type="text"/>	Source Of Information <input type="button" value=""/>				
Remarks <input type="text"/>						